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ABSTRACT	
	
Introduction:	
	Testosterone	is	frequently	used	as	part	of	postmenopausal	hormone	therapy	(HT)	but	few	preparations	have	been	approved	for	use	in	women.	The	effects	of	androgens	on	the	female	cardiovascular	(CV)	system	remain	poorly	understood	and	concerns	exist	over	the	long-term	CV	safety	of	testosterone	therapy.	This	study	aimed	to	investigate	the	CV	effects	of	the	transdermal	testosterone	patch	(TTP)	in	postmenopausal	women,	on	concomitant	HT,	using	surrogate	markers	for	CV	disease.		
Methods:	
	This	open	label	pilot	study	investigated	the	effects	of	12	weeks	TTP	on	arterial	stiffness	and	endothelial	function	in	21	postmenopausal	women.	Primary	outcome	measures	were	augmentation	index	(AIx),	assessed	by	pulse	wave	analysis	(PWA),	reactive	hyperaemic	index	(RHI)	using	peripheral	arterial	tonometry	(PAT)	and	insulin	resistance	using	the	homeostasis	model	(HOMA-IR).	Libido	(brief	profile	of	female	sexual	function	(B-PFSF)),	anthropometry,	lipids	and	serum	hormone	levels	were	also	assessed.		
Results:	
	Testosterone	was	associated	with	significantly	improved	libido	(increased	B-PFSF	score	5.05	points	(p<0.0001)),	increased	total	testosterone	(1.3	nmol/L,	p<0.0001)	and	free	androgen	index	(2.0,	p<0.001).	Hip	circumference	significantly	reduced	(-0.74	cm,	p<0.05)	but	there	was	no	change	in	weight,	body	mass	index,	waist	circumference	or	blood	pressure.			Total	cholesterol	was	unchanged,	but	there	were	small	but	significant	decreases	in	high-density	lipoprotein	(HDL)	cholesterol	(-0.25	mmol/L,	p<0.05)	and	lipoprotein	(a)	levels	(-3.11mg/L	,	p<0.05).	Fasting	insulin,	fasting	glucose	and	insulin	resistance	were	unchanged.	
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There	was	no	change	to	AIx	(1.07,	95%	CI	-3.85-1.72,	p=0.43),	or	RHI	(0.06,	95%	CI	0.19-0.31,	p=0.61)	but	there	was	a	significant	increase	in	salbutamol-mediated	vasodilatation	(p<0.05),	assessed	by	PWA.		
Conclusion:	These	data	suggest	that	short-term	physiological	testosterone	does	not	adversely	affect	arterial	stiffness	and	may	improve	markers	of	endothelial	function.	Testosterone	use	was	associated	with	reductions	in	HDL	cholesterol	and	lipoprotein	(a),	but	whether	this	has	significant	long-term	CV	effects	remains	unclear.	
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INTRODUCTION	
	Although	commonly	perceived	as	a	male	hormone,	testosterone	is	the	most	prevalent	active	sex	steroid	in	women	(1)	and	it	plays	a	crucial	role	in	normal	female	physiology.	Androgen	levels	decline	gradually	throughout	life	and	deficiency	can	be	associated	with	a	multitude	of	symptoms.	Improved	awareness	of	the	detrimental	effects	of	androgen	deficiency	has	led	to	increasing	use	of	testosterone	replacement	within	postmenopausal	hormonal	therapy	regimens,	particularly	for	women	suffering	from	reduced	sexual	desire.			Despite	significant	evidence	demonstrating	the	short-term	benefits	of	postmenopausal	testosterone	therapy	(2)	there	is	a	scarcity	of	products	designed	for	use	in	women	and	few	regulatory	authorities	have	approved	these	preparations.	Furthermore,	although	testosterone	replacement	has	been	used	in	women’s	health	for	many	years,	few	studies	have	examined	the	long-term	safety	of	androgen	therapy.	Particular	concerns	have	been	expressed	regarding	the	long-term	effects	of	testosterone	replacement	on	the	cardiovascular	system	and	breast	(3).		Cardiovascular	disease	(CVD)	is	the	leading	cause	of	death	in	postmenopausal	women	(4)	and	optimising	cardiovascular	risk	is	a	global	health	issue	(5).	The	relationship	between	androgens	and	the	cardiovascular	system	is	complex,	particularly	in	women.	Although	it	was	traditionally	thought	that	androgens	adversely	affect	cardiovascular	risk,	there	are	increasing	data	which	challenge	these	views	(6).			As	with	postmenopausal	estrogen-progestogen	hormone	therapy	(HT),	there	has	been	a	move	with	female	androgen	replacement	away	from	high	dose	parenteral	preparations	to	physiological	replacement	via	lower	dose	transdermal	or	subcutaneous	preparations.		There	are	many	plausible	reasons	why	this	approach	may	avoid	or	reduce	adverse	effects,	including	the	avoidance	of	first	pass	hepatic	metabolism	and	through	achieving	lower,	but	more	consistent,	serum	androgen	levels.	The	benefits	of	transdermal	compared	to	oral	estrogen	are	well	documented	(7,8),	however	there	has	been	a	paucity	of	data	investigating	the	benefits	of	the	newer,	physiological	methods	of	female	androgen	therapy.	Gold	standard	investigation	of	the	long-term	safety	outcomes	of	
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hormonal	preparations	requires	large	scale	randomised	or	observational	data.	Such	studies	can	take	many	years	to	achieve	results	and	are	an	enormous	financial	burden.	In	their	absence	we	can	make	use	of	surrogate	markers	for	disease	to	try	and	obtain	results	in	a	realistic	setting	and	timescale.		The	present	study	explores	the	effects	of	postmenopausal	transdermal	testosterone	on	the	cardiovascular	system	by	assessing	the	effects	of	the	transdermal	testosterone	patch	on	risk	factors	and	surrogate	markers	for	cardiovascular	disease.	
	
	 	
	 16	
LITERATURE	REVIEW	
	
Androgen	Physiology		Androgens	are	sex	steroid	hormones,	produced	in	women	by	both	the	adrenal	gland	and	the	ovaries,	with	many	important	roles	in	female	physiology.	In	premenopausal	women,	androgens	such	as	testosterone	and	androstenedione	are	produced	by	ovarian	theca	cells,	where	they	are	either	secreted	directly	into	the	circulation,	or	converted	by	granulosa	cells	into	estrogens	by	the	aromatase	enzyme.	Additionally,	the	adrenal	gland	produces	the	relatively	weak	androgens	dihydroepiandrosterone	(DHEA)	and	its	sulfate	(DHEA-S),	which	act	as	precursor	hormones	in	the	production	of	testosterone	via	peripheral	conversion	(Figure	1).	It	is	estimated	that	ovarian	and	adrenal	production	each	contribute	25%	of	circulating	testosterone	and	the	remaining	50%	is	contributed	through	conversion	of	androgen	precursors	in	peripheral	cells	and	target	organs	(9).	Two-thirds	of	testosterone	circulates	bound	to	sex	hormone	binding	globulin	(SHBG)	and	one-third	bound	to	albumin,	with	only	the	remaining	1-2%	circulating	freely	in	a	biologically	active	form	(10).	Testosterone	only	binds	to	albumin	with	relatively	weak	affinity	and	therefore	‘bioavailable’	testosterone,	i.e.	that	with	the	ability	to	diffuse	across	cell	membranes,	is	often	considered	as	the	free	testosterone	plus	the	albumin	bound	fraction.	Bioavailable	testosterone	can	therefore	be	strongly	influenced	by	the	many	factors	which	affect	SHBG	levels,	including	obesity	or	exogenous	estrogens.		Testosterone	circulates	in	women	at	around	5%	of	the	level	found	in	men	but	is	the	most	abundant	active	sex	hormone	(11).	Women	produce	around	3-4	times	more	testosterone	daily	than	estrogen,	equating	to	approximately	100-400µg	testosterone	per	day	(12).	Plasma	levels	of	testosterone	fluctuate	during	different	phases	of	the	menstrual	cycle	(13),	being	lowest	in	the	early	follicular	phase	with	significant	mid-cycle	elevations	(14).	Levels	also	show	circadian	variation,	being	highest	in	the	early	morning.		The	level	of	circulating	androgens	declines	gradually	with	age,	primarily	owing	to	a	reduction	in	adrenal	production	of	androgens	and	androgen	precursors.	It	is	estimated	that	androgen	levels	decline	by	50%	between	the	ages	of	20	and	40	years	(15).	Current	
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data	do	not	point	to	a	precipitous	drop	in	androgen	production	at	natural	menopause	(16)	and	after	menopause	the	ovaries	remain	an	important	source	of	androgen	production	(15).	Atrophy	of	the	adrenal	cortex	reduces	the	contribution	from	the	adrenal	gland	to	around	10%	of	circulating	androgens,	with	50%	from	the	ovaries	and	40%	from	peripheral	conversion	(17).	This	is	in	keeping	with	studies	which	demonstrate	a	40-50%	drop	in	testosterone	following	surgically	induced	menopause	(18,19).	As	well	as	age-related	decline	and	surgical	oophorectomy,	other	causes	for	androgen	deficiency	include	premature	ovarian	insufficiency	(POI)(20),	hypogonadotrophic	hypogonadism	(21),	hypopituitarism	(22),	hyperprolactinaemia	and	oral	estrogen	or	glucocorticoid	therapy.		Changes	in	estradiol	levels	at	menopause	are	also	thought	to	influence	androgen	production,	both	by	removal	of	the	negative	feedback	and	the	reduction	in	SHBG	production	associated	with	the	hypoestrogenic	environment.	The	result	is	a	relatively	androgenic	hormonal	milieu	in	postmenopausal	women,	indeed	some	data	suggest	an	increase	in	free	androgen	index	in	the	perimenopausal	years	(23).		
Figure	1.	Female	androgen	production.	Dihydoepiandrosterone	sulphate	(DHEAS),	dihydroepiandrosterone	(DHEA),	dihydrotestosterone	(DHT).	Percentages	demonstrate	contributing	source	for	each	androgen	
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The	exact	role	of	androgens	in	women	remains	poorly	understood	(24)	due	to	the	complex	metabolic	pathways	involved.	Testosterone	is	thought	to	exert	its	wide-ranging	effects	through	3	principal	mechanisms	(Figure	2).	Its	primary	mode	of	action	involves	activation	of	the	androgen	receptor	(AR).	ARs	are	found	in	almost	all	tissues	throughout	the	body	including	brain,	skin,	adipose,	bone	and	the	vascular	tree.	AR	activation	results	in	direct	genomic	effects	in	target	cells	which	can	be	modulated	by	a	variety	of	co-regulator	proteins	(25).	Testosterone	can	also	have	more	rapid,	non-genomic	effects	by	activating	membrane	bound	receptors	which	exert	their	actions	via	activation	of	2nd	messenger	pathways	(26).	Furthermore,	as	a	proportion	of	testosterone	is	converted	within	target	cells	to	estradiol	by	the	aromatase	enzyme,	it	is	unclear	to	what	extent	the	effects	of	testosterone	are	mediated	directly	or	through	the	actions	of	estradiol.		
Figure	2.	Mechanisms	of	testosterone	action.	Modified	from	(25).	(1)	Direct	activation	of	androgen	receptor	(AR)	by	testosterone	(T)	or	dihydrotestosterone	(DHT).	(2)	Rapid,	non-genomic	response	via	specific	membrane	binding	sites	(SMBS)	and	intracellular	secondary	messenger	pathways.	(3)	Intracellular	conversion	to	estradiol	(E2)	and	activation	of	estrogen	receptor	(ER).	
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Androgen	deficiency	Although	free	and	total	testosterone	concentrations	have	not	been	shown	to	correlate	well	with	measures	of	sexual	function	(27),	exogenous	testosterone	has	long	been	recognised	to	improve	female	sexual	function	and	other	aspects	of	physical	and	psychological	well-being	(28).	Terms	such	as	‘relative	androgen	deficiency’	(15)	or	‘female	androgen	insufficiency	syndrome’	(29)	have	been	proposed	to	characterize	the	collection	of	symptoms	which	may	be	associated	with	low	testosterone	(Table	1).	However,	the	use	of	these	terms	has	been	controversial,	due	to	the	lack	of	a	clear	definition	and	often	non-specific	nature	of	symptoms	(30).		Current	recommendations	suggest	that	androgen	deficiency	should	be	a	clinical	diagnosis,	particularly	in	view	of	the	inherent	problems	associated	with	serum	testosterone	measurement	in	women	and	the	poor	understanding	of	age-related	normal	reference	ranges	(31).	Furthermore,	data	correlating	testosterone	levels	with	symptoms	are	lacking	(32).	Menopause	symptom	rating	scales	have	been	adopted	for	use	in	androgen	deficiency	and	in	clinical	studies	have	proved	a	useful	tool	for	assessing	symptoms	severity	and	response	to	treatment	(33).	It	is	hoped	that	further	validation	of	these	questionnaires	will	generate	a	standardised	diagnostic	tool	for	androgen	deficiency.	Although	assessment	of	testosterone	levels	does	not	appear	to	have	a	role	in	diagnosis,	it	is	generally	recommended	that	baseline	levels	be	established	prior	to	treatment	and	to	identify	patients	who	may	be	at	risk	of	developing	supraphysiological	levels	(2).								
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Table	1.	Symptoms	associated	with	androgen	deficiency	(1,34).									
	
	
	
	
	
	
Postmenopausal	testosterone	therapy	
• Testosterone	preparations	Testosterone	has	been	used	in	the	field	of	gynaecology	for	over	70	years,	initially	being	used	as	a	treatment	for	menorrhagia,	dysmenorrhoea,	mastalgia,	and	pelvic	inflammatory	disease	(35).	As	early	as	the	1950s	it	was	recognised	that	androgens	may	play	a	role	in	the	management	of	climacteric	symptoms	(36),	with	studies	demonstrating	that	combination	estrogen-androgen	therapy	appeared	to	benefit	sexual	desire	compared	to	estrogen	alone.	For	several	decades	androgen	replacement	was	administered	orally	and	subsequently	via	intramuscular	injection	or	subcutaneous	implant,	often	in	supraphysiological	doses.	Concerns	consequently	arose	due	to	the	high	incidence	of	androgenic	side	effects	associated	with	parenteral	routes.	More	recently,	attention	has	turned	towards	transdermal	testosterone	replacement	using	patches	or	gel/cream.	The	transdermal	route	achieves	a	more	constant,	
Symptoms	of	androgen	deficiency	
Low	sexual	desire	Reduced	sense	of	well-being	Dysphoric	mood	Low	energy/reduced	motivation	Bone	loss	Reduced	muscle	strength	Poor	cognition	and	memory	Insomnia	Vasomotor	symptoms	Joint	pain	Urinary	dysfunction	
	 21	
physiological	serum	hormone	level	(37)	and	the	avoidance	of	first	pass	hepatic	metabolism	may	help	reduce	unwanted	effects	on	hepatic	proteins.	Several	randomised	placebo-controlled	trials	investigating	the	use	of	a	transdermal	testosterone	patch	(TTP)	in	treating	hypoactive	sexual	desire	disorder	(HSDD)	reported	significant	improvements	in	sexual	desire	and	other	domains	of	sexual	function	both	with	(38–42)	and	without	(43)	concurrent	HRT	use.	This	was	also	associated	with	an	improved	sense	of	well-being	(38,39).	The	results	of	these	trials	led	to	the	UK	and	European	licensing	of	Intrinsa	(300ug/day	testosterone)	(©	Warner	Chilcott)	for	the	treatment	of	hypoactive	sexual	desire	disorder	(HSDD)	in	surgically	menopausal	women	also	taking	estrogen.	The	Intrinsa	license	was	voluntarily	removed	by	Warner	Chilcott	in	2012	for	commercial	reasons.	Off-label	use	of	testosterone	gels/creams	is	common,	but	no	preparations	designed	for	use	in	women	are	currently	recognised	by	the	UK	or	European	regulatory	authorities	or	by	the	FDA	in	the	US.	The	subcutaneous	implants,	which	were	licensed	for	30	years	for	use	in	surgically	menopausal	women	on	concomitant	estrogen	are	no	longer	available.	
	
• Post-menopausal	testosterone	replacement	for	low	sexual	desire	
Low	sexual	desire	is	a	common	problem	amongst	women	of	all	ages,	particularly	in	middle	age.	When	associated	with	distress,	it	is	termed	hypoactive	sexual	desire	disorder	(HSDD),	which	is	estimated	to	affect	approximately	9-14%	of	postmenopausal	women	(44).	HSDD	has	a	significant	impact	on	physical	and	psychological	wellbeing,	having	been	associated	with	low	self	esteem	(45),	depression	(46),		psychological	distress	(47),	and	reduced	quality	of	life	(48).	Women	with	low	desire	are	also	more	likely	to	experience	lower	arousal	and	pleasure,	orgasmic	difficulties	and	suffer	dissatisfaction	with	their	sex	life	and	partner	relationship	(45).	Healthy	female	sexual	function	is	the	result	of	complex	interactions	between	a	multitude	of	physiological,	psychological	and	social	factors,	including	estrogen	or	androgen	deficiency	(49).	
Androgen	replacement	has	long	been	recognised	to	play	a	role	in	improving	sexual	desire,	particularly	in	postmenopausal	women.	In	early	observational	studies,	postmenopausal	women	using	subcutaneous	estradiol	and	testosterone	implants	
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reported	significant	improvements	in	sexual	function	(50);	findings	that	were	later	corroborated	in	randomised	studies	(51).	Similarly	beneficial	effects	on	sexual	desire	were	also	reported	in	randomised	studies	involving	oral	testosterone,	used	in	both	naturally	and	surgically	menopausal	women	(52,53).	Although	an	effective	treatment,	oral	therapy	often	resulted	in	supraphysiological	doses	and	unacceptably	high	rates	of	androgenic	side	effects.	Furthermore,	concerns	arose	about	the	long	terms	effects	of	treatment,	particularly	the	risk	of	CVD,	due	to	reported	adverse	effects	to	the	lipid	profile	and	to	insulin	resistance.	This	led	to	the	search	for	other	methods	of	delivery	and	most	recent	research	has	concentrated	on	achieving	physiological	replacement	via	transdermal	or	subcutaneous	routes.	
The	development	of	the	TTP	led	to	a	plethora	of	randomised	controlled	trials	(RCTs)	investigating	the	safety	and	efficacy	of	this	product.	In	a	study	by	Shifren	et	al.,	75	surgically	menopausal	women,	with	impaired	sexual	function	and	who	were	also	taking	conjugated	estrogens,	were	randomised	to	the	TTP	or	placebo.	The	TTP	was	associated	with	significantly	improved	sexual	function	as	determined	by	scores	on	the	Brief	Index	of	Sexual	Functioning	for	Women	(54).		
A	further	randomized,	placebo-controlled	phase	2	study	sought	to	examine	the	dose	response	effect	of	the	TTP	in	surgically	menopausal	women	on	concomitant	oral	estrogen	(41).	Subjects	were	randomized	to	receive	placebo	(n	=	119)	or	testosterone	patches	in	dosages	of	150	microgram/day	(n	=	107),	300	microgram/day	(n	=	110),	or	450	microgram/day	(n	=	111)	twice	weekly	for	24	weeks.	The	results	showed	that	only	the	300	microgram	dose	was	associated	with	significant	increases	in	sexual	desire	and	frequency	of	satisfying	sexual	activity,	but	no	significant	benefit	was	derived	from	either	the	150	or	450	microgram	doses.	The	authors	suggest	300	micrograms/day	may	be	the	top	end	of	the	dose	response	curve,	which	would	explain	the	lack	of	additional	efficacy	of	the	450	microgram	dose.	Furthermore,	mean	testosterone	production	in	women	is	approximately	300	microgram/day	and	therefore	the	higher	dose	results	in	supraphysiological	replacement,	which	may	alter	the	in	vivo	effects.	
These	studies	were	then	followed	by	two	larger	phase	3	studies	(INTIMATE	SM1	AND	2)	(40,42)	involving	a	total	of	1094	surgically	menopausal	women.	Again,	the	300microgram	testosterone	patch	in	addition	to	estrogen	was	associated	with	
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significantly	more	satisfying	encounters	and	increased	sexual	desire.	Debate	ensued	as	to	whether	a	small	increase	in	frequency	of	satisfying	sexual	activity	(an	additional	1-2	episodes	over	4	weeks)	was	clinically	meaningful,	although	crucially,	these	improvements	in	sexual	function	were	associated	with	a	reduction	in	distress	levels.	
The	TTP	only	received	a	license	for	use	in	surgically	menopausal	women	using	systemic	estrogen,	however	there	are	large	scale	RCT	data	to	support	its	use	out	with	this	population.	Significant	increases	in	sexual	desire,	satisfying	sexual	activity	and	reductions	in	distress	have	also	been	observed	in	naturally	menopausal	women	on	HT	(39),	naturally	postmenopausal	women	predominantly	not	on	HT	(55)	and	postmenopausal	women	not	on	concomitant	HT	(43).	More	recently,	the	benefits	of	the	TTP	in	women	suffering	from	selective	serotonin	reuptake	inhibitor	(SSRI)	or	serotonin	noradrenalin	reuptake	inhibitor	(SNRI)	associated	low	libido	have	been	observed.	Administration	of	the	TTP	was	associated	with	a	significant	increase	in	4	week	frequency	of	satisfying	sexual	episodes	compared	to	placebo	(2.3	vs	0.1,	p=0.02)	(56).	
Testosterone	creams	(licensed	in	Australia)	and	gels	(usually	male	products,	used	‘off-label’)	have	also	been	gaining	interest	and	data	exist	to	support	their	use.	In	a	randomized,	placebo-controlled,	cross	over	study	in	53	postmenopausal	women	with	low	libido	on	HT,	Nathorst-Boos	et	al.	report	that	10mg	daily	of	testosterone	gel	was	associated	with	significant	improvements	in	desire,	including	frequency	of	sexual	activity,	fantasies	and	sexual	interest	(57).	Although	usually	administered	on	a	regular	basis,	there	are	pilot	data	which	suggest	benefit	from	using	testosterone	gel	on	an	‘as-required’	basis.	In	a	small	randomized	double-blind	cross	over	study,	a	single	dose	of	testosterone	gel	administered	4-8	hours	prior	to	intercourse	in	premenopausal	women	with	HSDD	resulted	in	increased	arousal	(58).	Further	data	are	required	to	confirm	these	findings,	particularly	as	the	use	of	testosterone	in	premenopausal	women	has	not	been	well-studied.	
A	further	area	of	interest	is	the	potential	effect	of	local	vaginal	testosterone	application.	A	study	by	Witherby	and	colleagues	(59)	investigated	the	use	of	topical	testosterone	cream	for	the	treatment	of	vulvovaginal	atrophy	in	20	postmenopausal	patients	with	breast	cancer	who	were	taking	aromatase	inhibitors.	Testosterone	cream	was	applied	to	the	vaginal	epithelium	daily	for	28	days	and	was	associated	with	a	significant	
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improvement	in	dyspareunia,	vaginal	dryness	and	vaginal	maturation	index	without	increasing	estradiol	or	testosterone	levels.	
The	most	recent	systematic	review	and	meta-analysis	of	postmenopausal	testosterone	use	identified	35	RCTs	(n=5053)	and	confirmed	that	testosterone	therapy	was	associated	with	increased	sexual	activity,	increased	interest	in	sex,	improved	quality	of	sexual	encounters	and	improved	sexual	self	image	(60).	In	subgroup	analysis,	testosterone	was	more	effective	than	methyl-testosterone	or	testosterone	undecanoate	at	improving	sexual	function.	In	further	sub-group	analysis,	no	significant	differences	were	found	dependent	on	route	of	testosterone,	use	of	concomitant	HRT,	or	type	and	route	of	estrogen	use.	
	
• Systemic	benefits	of	testosterone	therapy	
	
o Well	being	and	quality	of	life	
Although	HSDD	is	the	main	indication	for	postmenopausal	testosterone	use,	several	other	beneficial	effects	have	been	reported.	Improved	quality	of	life,	mood	and	overall	well	being	has	consistently	been	noted	(38,39,54,61).	A	recent	observational	study	examined	the	use	over	3	months	of	75-160	mg	testosterone	implants,	without	concomitant	estrogen,	in	300	pre-menopausal	and	post-menopausal	women	reporting	symptoms	of	androgen	deficiency	such	as	sexual	problems,	fatigue,	mood	disturbance,	headaches,	insomnia,	memory	loss	and	hot	flushes.	Testosterone	implants	were	found	to	be	effective	for	the	relief	of	psychological,	somatic	and	urogenital	symptoms,	in	addition	to	sexual	desire,	with	a	dose-dependent	response	(33).			
o Cognitive	function	
Based	on	endogenous	testosterone	levels,	a	potential	neuroprotective	role	for	testosterone	has	been	suggested	(62,63).	Recent	data	have	suggested	that	transdermal	testosterone	many	improve	cognitive	performance,	although	there	are	few	high	quality	RCTs	(2,64).	The	use	of	testosterone	gel	in	postmenopausal	women	also	using	estrogen	was	associated	with	improvement	in	immediate	and	delayed	verbal	memory	(65).	In	a	
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more	recent	RCT,	92	postmenopausal	women,	not	on	systemic	estrogen	therapy,	were	randomised	to	300mcg	testosterone	gel	or	placebo.	After	26	weeks	of	therapy	there	was	significant	improvements	in	verbal	learning	and	memory	in	the	testosterone	group	(66).	
o Bone	density	
Androgens	can	also	act	to	inhibit	bone	resorption	and	therefore	it	has	been	suggested	that	exogenous	testosterone	may	benefit	bone	density.	Although	no	studies	have	examined	fracture	rates	as	a	clinical	endpoint,	there	are	data	that	testosterone	implants	(67)	and	combined	oral	estrogen-methyltestosterone	(MT)	therapy	may	improve	bone	density	(68,69).	However,	conflicting	data	exist,	as	a	further	study	found	improvements	in	bone	mineral	density	(BMD)	in	both	estrogen	and	estrogen-androgen	treated	groups,	with	no	significance	difference	observed	between	groups	(70).		
Few	studies	have	examined	the	effect	of	transdermal	testosterone	on	BMD	in	postmenopausal	women.	In	a	study	investigating	the	effects	of	transdermal	testosterone	on	bone	density	in	145	women	with	POI,	the	addition	of	150mcg	transdermal	testosterone	to	100mcg	transdermal	estradiol	and	sequential	progestogen	did	not	result	in	any	additional	benefit	to	BMD	over	the	3-year	study	period	compared	to	placebo	(71).	In	contrast,	300mcg	TTP	was	associated	with	significant	increases	in	BMD	in	women	with	hypopituitarism	(72).	
	
• Safety	Concerns	
There	are	compelling	data	highlighting	the	benefits	of	postmenopausal	testosterone	use	and	position	statements	from	several	endocrine	and	menopause	societies	support	the	use	of	androgens	for	postmenopausal	women	suffering	from	distressing	low	sexual	desire	(32,73–75).	Despite	this,	the	use	of	testosterone	remains	controversial	and	few	regulatory	authorities	have	approved	its	use.	In	the	UK,	implants	and	the	TTP	are	licensed	in	surgically	menopausal	women,	however	the	US	Food	and	Drug	Administration	(FDA)	has	not	approved	any	testosterone	preparations	for	the	treatment	of	low	sexual	desire	in	postmenopausal	women.	Of	primary	concern	to	
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regulatory	authorities	is	the	lack	of	long-term	safety	data,	particularly	with	regard	to	the	risk	of	breast	or	endometrial	cancer	and	CVD	(3,30).	Many	of	these	concerns	have	been	extrapolated	from	the	findings	from	the	Women’s	Health	Initiative	(WHI)	studies,	due	to	the	potential	for	testosterone	to	be	converted	to	estradiol.	To	date,	clinical	trials	have	predominantly	focused	on	safety	data	in	terms	of	androgenic	events,	site	reactions	and	basic	blood	parameters.	Reviews	of	the	subject	have	emphasised	the	need	for	improved	long-term	safety	data	(76).	
o Androgenic	side	effects	
Androgenic	side-effects	(hirsutism,	acne,	alopecia	and	rarely,	virilisation)	are	associated	with	supraphysiological	testosterone	doses.	Androgenic	side	effects	from	transdermal	physiological	therapy	are	generally	mild	and	take	several	months	to	occur.	They	are	usually	dose	dependent	and	resolve	after	treatment	is	discontinued.	
The	incidence	of	hirsutism	in	the	TTP	RCTs	was	estimated	at	3-20%.	A	statistically	significant	increase	in	hirsutism	was	observed	in	only	one	study	(43).	This	study	was	the	longest	in	duration	(52	weeks),	however	subjects	were	not	on	concomitant	estrogen,	which	may	have	contributed	to	the	findings.	
In	the	majority	of	studies	there	was	no	observed	increase	in	acne	compared	to	placebo	(incidence	4.6-7.5%	participants).	One	study	reported	a	significant	increase	in	acne	in	TTP	users,	however	both	groups	had	a	particularly	high	incidence	of	acne	(18%	of	TTP	users,	13%	of	controls)	(41).	
Nachtigall	and	colleagues	performed	a	4-year	follow-up	analysis	of	1,094	subjects	from	two	of	the	TTP	RCTs	with	a	mean	duration	of	use	of	1.1	years.	Overall	rates	of	androgenic	events	were	28.4%	(0-12	months),	14.3%	(12-24months),	10.5%	(24-36	months)	and	3.5%	(36-48	months).	Reported	events	were	mostly	mild	and	did	not	result	in	discontinuation	of	treatment	(77).	
The	more	severe	androgenic	effect	of	virilisation	(voice	deepening,	frontal	hair	loss	and	clitoromegaly)	is	extremely	rare,	and	tends	to	only	occur	when	sustained	supraphysiological	levels	of	testosterone	occur	via	parenteral	routes.	It	did	not	occur	in	any	studies	investigating	the	TTP.	
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o Breast	safety	
Concerns	have	been	raised	about	the	risk	of	breast	cancer	with	testosterone	replacement	(3).	In	fact,	available	data,	both	experimental	and	observational,	point	towards	no	increased	risk	in	breast	cancer	from	testosterone	therapy	(34).	There	are	relatively	few	clinical	trial	data	examining	the	effect	of	exogenous	testosterone	on	breast	cancer	risk	and	no	RCTs	with	breast	cancer	as	a	primary	outcome.	Available	studies	investigating	non-oral	routes	of	testosterone	replacement	have	produced	more	reassuring	results	than	those	using	oral	or	intramuscular,	often	high-dose,	therapy.	
Two	studies	have	suggested	an	association	with	breast	cancer	and	testosterone	replacement.	An	early	case–control	study	reported	that	the	risk	of	breast	cancer	was	increased	in	women	using	intramuscular	testosterone	in	addition	to	estrogen	or	estrogen	plus	progestogen	therapy	(78).	In	the	Nurses	Health	Study,	24	year	follow-up	contributing	1,359,323	person	years	of	data	and	4610	incident	breast	cancer	cases,	found	an	increased	risk	in	combined	estrogen	and	testosterone	users	compared	with	never	users	(RR:	2.48,	95%	CI:	1.53–4.0)	(79).	In	contrast,	data	from	the	WHI	observational	arm	with	a	mean	follow-up	of	10	years	reported	no	increased	risk	of	breast	cancer	with	CEE+MT	(80).		A	further	6	six	observational	studies	found	no	increased	risk	of	breast	cancer	associated	with	postmenopausal	testosterone	use	(81–86).	Randomized,	placebo-controlled	studies	showed	no	adverse	effects	from	the	TTP	on	breast	cell	proliferation	(87)	and	mammographic	density	(88,89).	
The	effects	of	androgens	may	be	mediated	either	directly	via	the	androgen	receptor,	which	has	been	demonstrated	in	breast	tissue,	or	from	conversion	to	estradiol	by	the	aromatase	enzyme	which	is	found	in	breast	tissue.	It	has	also	been	suggested	that	testosterone	may	have	further	indirect	effects	on	the	breast	by	influencing	SHBG	levels	and	subsequently,	the	bioavailability	of	estradiol	(90).	
Experimental	data	investigating	the	effects	of	androgens	on	breast	cell	lines	are	conflicting,	with	both	proliferative	(91)	and	anti-proliferative	(92–95)	effects	reported.	Other	studies	have	demonstrated	that	testosterone	is	pro-apoptotic	and	may	inhibit	gene	expression	in	breast	cells	(92,96,97).	This	led	to	an	interest	in	the	potential	protective	effect	of	androgens	on	the	breast	(96).	
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There	are	also	now	studies	reporting	the	beneficial	effects	of	testosterone	therapy	in	metastatic	breast	cancer	(98)	and	combination	testosterone-anastrazole	therapy	as	treatment	for	hormone	sensitive	breast	cancer	(99).	However,	there	is	evidence	to	suggest	differing	effects	of	testosterone	depending	on	tumour	hormone	status	(100–102)	and	further	studies	are	needed.	
	
o Endometrial	safety	
Epidemiological	data	have	reported	an	increased	risk	of	endometrial	cancer	in	association	with	raised	free	testosterone,	however	this	association	does	not	persist	after	adjustment	for	estrone	and	estradiol	levels	(103)	and	in	vitro	data	suggest	an	inhibitory	effect	of	androgens	on	endometrial	cell	proliferation	(104).	
There	are	a	lack	of	clinical	data	investigating	the	effects	of	testosterone	therapy	on	the	endometrium.	Only	one	randomized	study	has	examined	the	endometrial	effects	of	postmenopausal	testosterone	replacement	as	a	primary	outcome.	In	a	study	of	63	postmenopausal	women	randomised	to	either	2mg	estradiol,	testosterone	undecanoate	40mg	or	combined	therapy	with	both,	there	was	no	evidence	of	endometrial	thickness	or	proliferation	from	androgen	replacement	as	assessed	by	ultrasound	and	histopathology	(105).	The	Aphrodite	study	investigated	the	effects	of	the	TTP	in	women	not	on	concomitant	estrogen.	814	postmenopausal	women	using	the	TTP	were	followed	up	over	52	weeks	and	although	vaginal	bleeding	was	more	common	in	the	TTP	group	(10.6%)	compared	to	placebo	(2.6%),	no	subjects	developed	endometrial	hyperplasia	or	carcinoma	(43).	In	an	observational	case–control	study,	8412	women	were	followed-up	for	a	mean	of	4.4	years.	Of	the	2103	testosterone	users,	there	were	no	cases	of	endometrial	cancer	compared	with	five	cases	in	6309	controls	(81).	
Therefore	although	current	data	do	not	suggest	any	increased	risk	of	endometrial	cancer	in	association	with	testosterone	therapy,	further	long-term	studies	are	needed.	
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Cardiovascular	effects	of	testosterone	
• Gender-based	differences	in	cardiovascular	disease	
Cardiovascular	diseases	(CVD),	comprising	coronary	heart	disease	(CHD),	stroke	and	venous	thrombo-embolism	(VTE),	are	the	leading	cause	of	mortality	in	women,	responsible	for	almost	a	third	of	female	deaths	in	the	UK	(4).	Marked	gender	differences	exist	in	the	incidence	of	CVD	with	women	tending	to	develop	CVD	around	10	years	later	than	men	(106,107),	although	with	age,	particularly	after	menopause,	this	gender	difference	disappears.	This	observation	has	led	to	much	speculation	surrounding	the	cardioprotective	role	of	sex	steroids,	with	early	focus	on	the	potential	benefits	of	estrogens.	More	recently	though,	interest	has	been	turning	towards	a	potential	role	for	androgens	(6,108,109).		
Both	estrogens	and	androgens	are	implicated	in	the	gender-based	differences	in	CVD	incidence.		In	men,	high	androgen	levels	have	been	associated	with	detrimental	effects	to	important	CV	risk	factors	such	as	blood	pressure,	lipids	and	glucose	metabolism.	However,	more	recently	it	has	been	shown	that	low	circulating	testosterone	levels	are	associated	with	higher	mortality	rates,	mainly	due	to	increased	CVD	(110–116)	and	metabolic	syndrome	or	diabetes	(117).	This	has	subsequently	led	to	much	interest	in	the	potential	cardiovascular	benefits	of	male	androgen	therapy	(118,119).	
In	women,	the	CV	effects	of	androgens	are	much	less	well	understood	(25,109).	Several	potential	mechanisms	have	been	suggested	by	which	androgens	may	affect	CV	risk.	These	include	direct	effects	of	the	vasculature,	or	indirectly	via	effects	on	insulin	resistance,	fat	distribution	and	lipid	profile.		
Although	many	studies	have	investigated	the	effect	of	androgens	on	CV	risk,	results	are	frequently	conflicting	and,	to	date,	there	are	only	very	limited	data	which	can	be	applied	to	the	postmenopausal	use	of	testosterone.	There	is	marked	heterogeneity	amongst	available	studies	and	many	factors	to	consider	when	results	of	androgen	studies	are	being	interpreted	(Table	2).	
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Table	2.	Confounding	factors	which	affect	testosterone	studies	
• Endogenous	vs	exogenous	androgens	
• Physiological	or	supraphysiological	doses	
• Route	of	hormone	administration	
• Testosterone	assay	used	
• Testosterone	fraction	used	
• Concurrent	use	of	estrogen/progestogen	HT	
• Presence	of	other	CV	risk	factors	
	
	
• Molecular	studies	
Atherosclerosis	is	the	end	result	of	chronic	inflammation,	due	to	vascular	injury	and	endothelial	dysfunction.	Endothelial	injury	results	in	a	procoagulant	and	inflammatory	environment,	with	decreased	endothelial	production	of	vasodilators	such	as	nitric	oxide	(NO)	and	prostacyclin,	leucocyte	and	platelet	adhesion	and	aggregation,	and	smooth	muscle	cell	proliferation	and	migration	(120).	Persistent	inflammation	and	morphological	change	results	in	the	formation	of	atheromatous	plaques	which	are	characteristic	of	atherosclerosis.	Many	factors	will	affect	the	ability	of	the	endothelium	to	response	to	and	compensate	for	injury	but	central	to	this	process	is	the	ability	of	the	endothelium	to	produce	NO.	NO	is	a	crucial	regulator	of	endothelial	function	as	it	inhibits	endothelial	cell	monocyte	adhesion,	vascular	smooth	muscle	cell	migration	and	adhesion	and	platelet	aggregation.		
Androgen	receptors	are	present	throughout	the	cardiovascular	system,	including	endothelial	and	smooth	muscle	cells	and	myocardial	fibres	(25).	Molecular	studies	to	date	have	suggested	various	mechanisms	by	which	androgens	may	affect	CV	risk.	Older	
in	vitro	data	associated	testosterone	with	pro-atherogenic	effects	including	increased	apoptotic	damage	of	endothelial	cells	(121),	increased	migration	and	proliferation	of	vascular	smooth	muscle	cells	(122),	increased	adhesion	of	mononuclear	cells	to	the	
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endothelium	(123),	increased	oxidation	of	low-density	lipoprotein	(LDL)	cholesterol,	and	increased	vascular	cell	adhesion	molecule	(VCAM-1)	expression	(123).	
In	contrast,	there	is	now	accumulating	evidence	that	androgens	exert	a	beneficial	CV	effect	through	effects	on	vascular	function	(124).	Testosterone	causes	vasodilatation,	due	to	production	of	endothelium-derived	NO	in	and	via	effects	on	calcium	and	potassium	channels	in	smooth	muscle	(125).	In	vitro	data	have	shown	that	testosterone	rapidly	increases	endothelial	NO	production;	an	effect	not	affected	by	an	aromatase	inhibitor	and	completely	blocked	by	an	androgen	receptor	antagonist,	suggesting	that	this	is	a	direct	effect	of	the	AR	and	independent	of	conversion	to	estradiol	(126).	Other	beneficial	effects	of	testosterone	have	been	observed	including	reduced	monocyte	adhesion,	reduced	platelet	aggregation	(127),	decreased	VCAM-1	(128,129)	and	promotion	of	cholesterol	efflux	(130),	which	may	reduce	the	formation	of	fatty	streaks	characteristic	of	early	atherosclerosis.	
	
• Endogenous	testosterone	
A	deleterious	effect	of	hyperandrogenaemia	has	long	been	suggested	due	to	the	association	of	polycystic	ovarian	syndrome	(PCOS)	and	adverse	CV	risk	profile.	Women	with	hyperandrogenaemic	PCOS,	in	contrast	to	those	without	elevated	androgens,	have	increased	CV	risk	factors	including	obesity,	insulin	resistance	and	metabolic	syndrome	(131).	PCOS	is	associated	with	increased	CV	events	as	observed	in	longitudinal	studies,	event	after	adjustment	for	body	mass	index	(BMI)	(132).	
The	effects	of	endogenous	androgen	levels	in	postmenopausal	women	are	less	well	understood	as	conflicting	data	exist	(133).	Raised	endogenous	testosterone	has	been	linked	to	CVD	and	multiple	CV	risk	factors	(17).	It	has	also	been	suggested	that	SHBG	(which	has	a	direct	impact	on	free	testosterone	levels)	has	independent	predictive	power	for	CV	risk	(134,135).		
Some	(136–138)	but	not	all	studies	(139,140)	associate	endogenous	androgens	with	CV	risk	factors	including	increased	BMI,	increased	abdominal	obesity	and	raised	systolic	or	diastolic	blood	pressure.	Although	a	relationship	between	testosterone,	SHBG	and	
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obesity	has	been	observed,	data	from	the	Study	of	Women’s	Health	Across	the	Nation	suggests	that	weight	gain	across	the	menopause	transition	results	in	changes	in	hormone	levels	rather	that	the	reverse	(141).	
Although	the	majority	of	observational	data	does	not	support	a	role	for	endogenous	testosterone	and	lipid	metabolism	(17),	some	observational	and	clinical	studies		have	demonstrated	that	increased	androgenicity	is	associated	with	adverse	changes	to	the	lipid	profile	including	increased	total	cholesterol,	increased	LDL	cholesterol	and	reduced		high	density	lipoprotein	(HDL)	cholesterol	(142).	Other	studies	showed	that	SHBG	appears	more	important	and	that	androgen	levels	are	not	independent	predictors	of	risk	factors	for	CVD	(134).	
Several	cross-sectional	studies	have	examined	the	effects	of	endogenous	testosterone	levels	on	risk	of	CVD	using	surrogate	markers	and	CV	events,	but	results	are	conflicting.	An	inverse	relationship	between	endogenous	testosterone	and	CV	risk	was	found	in	studies	assessing	including	carotid	intima-media	thickness	(CIMT)(143,144)	and		carotid	atherosclerosis	on	ultrasound	(145).	A	case	control	study	found	that	post-menopausal	women	with	proven	carotid	artery	atherosclerosis	were	found	to	have	significantly	lower	levels	of	total	testosterone	compared	to	women	with	normal	carotid	arteries,	independent	of	other	CV	risk	factors	(146).	Wehr	et	al.	(147)	report	that	in	875	postmenopausal	women	referred	for	coronary	angiography,	low	free	testosterone	was	associated	with	CV	mortality	in	diabetic	women	but	not	in	non-diabetics.	
In	contrast,	other	studies	have	found	high	free	or	bioavailable	testosterone	to	be	associated	with	subclinical	atherosclerosis	as	assessed	by	CIMT	(148),	and	arterial	stiffness,	even	after	adjustment	for	estradiol	and	other	CV	risk	markers	(149).	A	further	small	study	in	26	postmenopausal	women	found	that	high	free	androgen	index	(FAI)	was	associated	with	endothelial	dysfunction	as	assessed	by	dorsal	hand	vein	vasodilation	(150).	Polymorphism	of	the	AR	gene	(CAG)n	repeat	was	associated	with	severity	of	CAD	and	risk	factor	profiles	in	131	postmenopausal	women	(151)	with	shorter	length	or	repeats	(suggesting	increased	AR	activity)	associated	with	increased	severity	of	CAD.	Other	studies	showed	a	correlation	between	high	testosterone	and	presence	of	coronary	artery	disease	at	angiography	(152).	In	a	study	by	Munir	et	al.,	increased	free	testosterone	was	associated	with	increased	calcified	and	non-calcified	
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coronary	artery	plaque	but	this	association	did	not	persist	after	adjustment	for	other	CV	risk	factors	(153).	
Several	other	large	cross	section	studies	did	not	find	a	relationship	between	endogenous	testosterone	and	surrogate	markers	including	coronary	artery	plaques	and	CIMT	(154),	abdominal	aortic	calcification	(155)	and	flow-mediated	vasodilatation	(156)	.		
There	are	few	data	which	link	endogenous	testosterone	levels	with	CV	events	and	mortality.	A	cross-sectional	study	in	344	older	postmenopausal	women	by	Patel	et	al.	found	that	women	in	the	top	quartile	of	total	testosterone	levels	had	a	3	fold	increased	in	risk	of	CHD	(OR	2.95,	95%	CI	1.2-73)	and	metabolic	syndrome	(OR	3.14,	95%	CI	1.57-6.35),	however	this	association	was	not	true	for	free	testosterone	(157).	In	another	study	the	association	between	FAI	and	increased	CV	risk	did	not	persist	after	adjustment	for	BMI	and	other	CV	risk	factors	(158).	Other	studies	also	(139,159)	showed	no	association	with	endogenous	testosterone	levels	and	CV	events.	
Five	longitudinal	studies	investigating	the	effects	of	androgens	in	postmenopausal	women	were	identified.	Karim	et	al.	demonstrated	that	that	a	higher	total	testosterone	was	associated	with	reduced	subclinical	atherosclerosis	progression	as	assessed	by	CIMT	over	2	years	(160).	In	a	cohort	study	of	438	Australian	women,	high	free	testosterone	but	not	total	testosterone	was	associated	with	increased	10	year	risk	of	coronary	event	(161).	
In	the	Rancho	Bernardo	study	651	Caucasian	postmenopausal	women	not	using	HT	were	followed-up	for	19	years.	There	was	no	association	between	free	or	total	testosterone	with	death	from	CHD	(139).	A	larger	prospective	cohort	study	found	that	in	2914	German	women	(of	whom	1394	were	postmenopausal),	those	in	the	lowest	quintile	of	total	testosterone	had	significantly	increased	mortality	(HR	0.62,	95%	CI	0.42-0.939)	and	risk	of	CV	events	(HR	0.68,	95%	CI	0.48-0.97)	(162).	A	further	prospective	population	based	study	by	Laughlin	et	al.	followed	639	postmenopausal	women	for	a	mean	of	12.3	years	with	134	CV	events.	The	results	showed	a	U-shaped	curve	for	CV	risk	with	those	in	the	highest	(HR	1.79,	95%CI	1.03-3.16)	and	lowest	(HR	1.	
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96	95%CI	1.13-3.41)	quintiles	for	free	testosterone	having	higher	risk	of	incident	CHD	events	(163).		
Many	of	these	studies	contain	heterogenous	populations	which	may	explain	the	conflicting	results.	Some	fail	to	adjust	for	estradiol	levels	and	CV	risk	factors	such	as	BMI.	Furthermore	it	is	unclear	whether	changes	in	sex	steroid	hormones	may	be	an	adaptation	to	a	disease	process	or	a	marker	of	poor	CV	health.	Overall	the	majority	of	data	appear	to	suggest	that	both	low	and	high	endogenous	testosterone	may	increase	CV	risk	and	it	has	therefore	been	suggested	that	optimisation	of	testosterone	levels	within	the	physiological	range	may	be	most	beneficial	for	CV	health	(163).	
	
• Exogenous	testosterone	
The	suggestion	that	there	may	be	CV	benefit	from	maintaining	testosterone	within	the	physiological	range	has	huge	potential	implications	given	the	global	burden	of	CVD.	Whether	this	benefit	can	be	derived	from	exogenous	replacement	remains	unknown.	Few	studies	have	investigated	the	CV	effects	of	postmenopausal	testosterone	therapy.	Current	data	often	involve	pharmacological	dosing	and	are	limited	to	effects	on	CV	risk	factors	or	surrogate	markers	rather	than	CV	events	or	mortality	as	a	primary	outcome.			
	
o Animal	data	
Testosterone	has	been	shown	to	have	vasodilatory	effects	in	a	variety	of	animal	models	(164,165).	In	a	study	by	Chou	et	al.	(165)	testosterone	treatment	was	associated	with	vasodilatation	in	canine	coronary	arteries	in	a	sex-independent	manner,	an	effect	that	was	at	least	in	part	mediated	by	endothelium-derived	nitric	oxide.	These	findings	have	also	been	confirmed	with	physiological	testosterone	replacement	in	androgen	deficient	oophorectomised	rats,	which	led	to	an	improvement	in	the	vasodilator	response	of	the	endothelium	(166).	More	recently,	physiological	testosterone	replacement	in	oophorectomised	rats	has	been	shown	to	enhance	the	cardioprotective	benefits	from	estrogen	replacement	alone	(167).	Liu	et	al.	demonstrated	that	estradiol	and	testosterone	replacement	alone	or	in	combination	reduced	myocardial	injury,	increased	
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myocyte	viability	and	improved	contractile	function.	Combination	treatment	appeared	to	be	more	effective	than	either	estradiol	or	testosterone	replacement	alone	(167).	
Although	most	animal	studies	point	to	a	beneficial	effect	of	testosterone	on	the	CV	system	conflicting	data	exist.	Testosterone	has	been	associated	with	CV	risk	factors	including	activation	of	the	renin-angiotensin	system	(168,169),	elevated	BMI	and	visceral	fat	(170).	In	hypercholesterolaemic	rabbits,	testosterone	therapy	was	associated	with	impairment	in	endothelium-dependent	vasodilation	(171).	Furthermore	supraphysiological	doses	of	testosterone	were	associated	with	doubling	of	atherosclerotic	plaque	burden	in	rabbit	(172)	and	primate	models	(170).	
	
o Human	Data	
	(1) BMI/weight	distribution	
Initial	studies	investigating	the	effect	of	testosterone	on	body	mass	reported	reductions	in	subcutaneous	fat	but	increases	in	BMI	and	visceral	fat,	however	these	studies	involved	high-dose	intra-muscular	testosterone	used	in	female-male	transsexuals	(173–175).		
Effects	in	postmenopausal	women	appear	to	show	benefits	in	lean	body	mass,	but	may	be	dependent	on	the	route	of	administration.	Oral	and	subcutaneous	implant	therapy	has	been	associated	with	increases	in	lean	body	mass	(61,176,177)	but	also	visceral	fat	mass	(178).		Treatment	with	the	TTP	was	not	associated	with	any	changes	in	BMI	over	24	weeks	(39)	but	a	study	involving	39	postmenopausal	women	randomised	to	testosterone	gel	or	placebo	reported	a	significant	reduction	in	BMI,	total	body	weight	and	abdominal	fat	(179).	
	(2) Lipid	profile	&	inflammatory	markers	
Several	studies	have	investigated	the	effect	of	exogenous	testosterone	on	lipids	and	the	effects	appear	to	be	largely	dependent	on	route	of	administration.	Oral	therapy	has	
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consistently	been	associated	with	a	beneficial	effect	on	triglyceride	levels	and	total	cholesterol	but	with	detrimental	effect	to	HDL	cholesterol	(61,68,69,178,180–183)	and	a	favourable	effect	on	apolipoprotein	C	(183).	
In	contrast,	no	impact	on	lipid	profile	has	been	observed	in	associated	with	transdermal	therapy	including	testosterone	gel	(179)	and	the	TTP	(77).		In	a	4	year	follow-up	study	of	967	surgically	menopausal	women	who	had	received	at	least	1	application	of	the	TTP,	no	alterations	in	lipids	were	observed	compared	to	the	placebo	group.	
Only	one	RCT	has	investigated	the	effects	of	postmenopausal	testosterone	replacement	on	inflammatory	markers.	In	50	surgically	menopausal	women	randomised	to	estradiol	and	placebo	or	testosterone	undecanoate	40mg,	testosterone	was	associated	with	counteraction	of	the	estrogen-induced	rise	in	C-reactive	protein	(184).		
(3) Blood	pressure	
In	a	pharmacokinetic	study	of	12	postmenopausal	women,	on	concomitant	estrogen,	inhaled	testosterone	was	associated	with	an	acute	fall	in	systolic	blood	pressure	(mean	reduction	of	10mmHg±12mmHg)	5	minutes	after	therapy	(185).	Other	studies	have	no	shown	change	in	blood	pressure	in	association	with	oral	(178),	subcutaneous	(186)	or	transdermal	therapy	(39).		
(4) 	Surrogate	cardiovascular	markers	
There	are	only	limited	data	investigating	the	effect	of	exogenous	testosterone	on	surrogate	markers	for	CVD.	In	a	small	study	involving	female-to-male	transsexuals,	high-dose	intramuscular	testosterone	was	associated	with	an	impairment	of	vascular	reactivity	(187).	Intramuscular	testosterone	and	estrogen	administration	resulted	in	increased	rates	of	severe	aortic	atherosclerosis	in	postmenopausal	women,	as	demonstrated	by	radiographic	detection	of	calcified	aortic	deposits	in	a	trial	by	Hak	et	
al.	(188).	Again	this	was	a	small	study	involving	pharmacological	testosterone	doses	but	despite	this	only	showed	a	small	effect	following	1	year	of	testosterone	therapy.	Penotti	
et	al.	(189)	investigated	the	effects	of	8	months	of	oral	testosterone	undecanoate	versus	placebo	in	addition	to	transdermal	estrogen	and	medroxyprogesterone	acetate	on	vascular	reactivity	in	40	postmenopausal	women.	They	found	a	small	but	significant	
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(6%,	p<0.05)	increase	in	the	pulsatility	index	of	the	middle	cerebral	artery,	a	reflection	of	the	vascular	reactivity	of	the	cerebral	arteries,	in	women	receiving	testosterone.		
	
In	contrast,	testosterone	has	been	associated	with	beneficial	endothelial	effects	including	acute	vasodilatation	with	inhaled	testosterone	(185)	and	chronic	vasodilatation	with	implant	therapy	(186).	The	study	by	Worboys	et	al.	assessed	the	effect	of	6	weeks	of	subcutaneous	testosterone	implant	in	48	postmenopausal	women	also	taking	estrogen.	Compared	to	the	control	group,	testosterone	was	associated	with	an	improvement	in	endothelium	dependent	(flow-mediated)	and	endothelium	independent	(GTN	induced)	brachial	artery	vasodilatation	suggesting	a	beneficial	role	for	exogenous	testosterone	in	vascular	reactivity	and	endothelial	function	(186)	Additionally,	DHEA	administered	to	healthy	postmenopausal	women	for	12	weeks	was	associated	with	improved	endothelial	function	as	assessed	by	brachial	artery	flow-mediated	vasodilatation	(190).	Although	DHEA	has	androgenic	actions,	it	may	exert	its	effects	by	a	variety	of	metabolites	and	therefore	the	implications	of	this	study	cannot	be	applied	directly	to	testosterone	treatment.	
In	summary,	although	there	is	some	evidence	for	the	beneficial	effect	of	testosterone	on	surrogate	markers	for	CVD,	no	studies	have	examined	the	effect	of	physiological	transdermal	testosterone	replacement	in	postmenopausal	women.	
	 (5) Cardiovascular	events	
Unfortunately	there	are	no	long-term	prospective	data	investigating	postmenopausal	testosterone	replacement	with	CV	events	as	a	primary	outcome.		A	retrospective	study	of	293	female	to	male	transsexuals	who	received	long	term	high	dose	testosterone	showed	no	increase	in	frequency	of	myocardial	infarction	(MI)	or	hypertension	and	no	excess	of	deaths	due	CVD	or	other	causes	compared	to	the	general	population	(191).		
A	pooled	analysis	of	5	phase	III	safety	studies	investigated	the	CV	effects	of	the	TTP.	2795	women	were	randomised	to	TTP	or	placebo	for	24-52	weeks	duration.	There	was	no	change	in	CV	risk	factors	(including	cholesterol,	triglycerides,	insulin,	glucose	and	
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blood	pressure),	although	increases	in	HDL	were	slightly	less	in	the	TTP	group	compared	to	placebo	group.	There	was	no	difference	in	the	number	of	CV	events	reported	during	the	treatment	phase	with	(2	MIs	and	2	strokes)	were	reported	in	placebo	patients	and	3	(2	MIs	and	1	stroke)	in	the	TTP	group	(192).		
The	results	from	a	large	randomised,	placebo-controlled	trial	investigating	the	CV	effects	of	transdermal	testosterone	gel	which	has	a	composite	of	CV	events	including	death,	non-fatal	myocardial	infarction,	non-fatal	stroke,	coronary	revascularization,	hospitalized	unstable	angina,	and	venous	thromboembolic	events	as	a	primary	end-point	are	still	awaited	(193).	It	was	hoped	that	this	study	would	provide	long-term	outcome	data	but	unfortunately	it	may	not	report	due	to	commercial	reasons.	
Although	there	are	data	to	suggest	that	high	dose	parenteral	or	oral	replacement	may	have	a	negative	impact	on	CV	risk	factors,	these	data	cannot	be	applied	to	physiological	replacement	via	subcutaneous	or	transdermal	routes.	Physiological	replacement	appears	to	have	a	beneficial	effect	on	CV	risk	factors	but	its	effect	on	surrogate	markers	and	long	term	CV	mortality	remains	unclear.	
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Testosterone	and	glucose	metabolism/insulin	resistance	Insulin	resistance	is	central	to	the	development	of	the	metabolic	syndrome	which	comprises	insulin	resistance,	central	obesity,	hypertension	and	dyslipidaemia	(194).	The	prevalence	of	obesity	and	metabolic	syndrome	in	women	increases	around	the	time	of	the	menopause	and	is	a	well-established	risk	factor	for	CV	disease.	
The	relationship	between	endogenous	androgens	and	glucose	metabolism	has	long	been	suspected	due	the	association	between	hyperandrogenism	and	insulin	resistance	seen	in	women	with	PCOS.	Women	with	PCOS	have	significantly	increased	risk	of	type	2	diabetes	compared	to	BMI	matched	controls	(HR	1.75,	95%	CI	1.51-2.02)(195).	
Circulating	testosterone	levels	appear	to	be	higher	in	diabetics	compared	to	non-diabetics	(196,197)	and	higher	circulating	testosterone	has	been	associated	with	raised	fasting	glucose	(198).	Analysis	from	the	Rancho	Bernardo	study	found	marked	sexual	dimorphism	in	the	relationship	between	endogenous	testosterone	and	insulin	resistance	(199).	In	their	analysis	of	233	postmenopausal	women	not	taking	estrogen,	there	was	a	3	fold	increased	risk	of	diabetes	in	women	in	the	highest	quartile	of	bioavailable	testosterone	(OR	2.9,	95%	CI	1.1-8.4)(199).		Other	studies	have	also	found	a	positive	correlation	between	free	and	total	testosterone	and	incident	DM	(200)	and	metabolic	syndrome	(201,202).		In	contrast,	other	longitudinal	studies	demonstrated	that	the	association	between	testosterone	and	risk	of	DM	did	not	persist	after	adjustment	for	confounding	factors	such	as	BMI	and	insulin	resistance	(203)	(204).	
Interpretation	of	these	findings	is	further	complicated	by	the	effects	of	SHBG,	which	is	known	to	be	a	strong	predictor	of	insulin	resistance,	an	effect	which	appears	to	be	independent	of	estrogen	and	androgen	levels	(205).	This	has	led	to	the	suggestion	that	declining	SHBG	levels	may	be	responsible	for	increasing	insulin	resistance	rather	than	primary	alterations	in	androgen	levels	(32).	
The	pathophysiology	underlying	the	relationship	between	androgens	and	glucose	metabolism	remains	poorly	understood.	Cause	and	effect	is	difficult	to	disentangle	as	insulin	can	act	as	a	co-gonadotrophin	with	luteinizing	hormone	to	stimulate	androgen	production	from	ovarian	theca	cells	(206).	Hyperinsulinaemia	is	associated	with	a	decrease	in	hepatic	SHBG	production,	resulting	in	higher	bioavailable	testosterone.		
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Conversely,	it	has	also	been	suggested	that	hyperandrogenism	may	affect	glucose	metabolism	and	insulin	sensitivity.	In	vitro	studies	have	shown	that	adipocytes	exposed	to	testosterone	have	reduced	insulin	mediated	glucose	uptake	(207).	Findings	in	oophorectomised	rats	treated	with	testosterone	showed	impaired	whole-body	insulin-mediated	glucose	uptake	which	was	thought	to	be	due	to	reductions	in	glycogen	synthase	expression	(208).	This	is	corroborated	by	a	study	investigating	the	treatment	of	PCOS	patients	with	spironolactone,	an	anti-androgen,	which	led	to	reduced	androgen	levels	and	improved	insulin	sensitivity,	independent	of	weight	change	(209).	Furthermore,	androgens	may	have	additional,	indirect	actions	on	glucose	metabolism	through	effects	on	lipid	profile	and	body	fat	composition.	The	most	commonly	accepted	view	is	that	there	is	a	complex	interplay	between	hyperandrogenism	and	hyperinsulinaemia	with	multiple	mechanisms	acting	in	vivo.	
Although	these	data	point	to	a	detrimental	effect	from	endogenous	androgens	on	glucose	metabolism,	the	implications	of	this	for	exogenous	testosterone	administration	have	not	been	well	established.	Several	studies	have	shown	that	high-dose	testosterone	therapy	in	healthy	young	women	can	result	in	reduced	peripheral	glucose	uptake	(210),	hyperinsulinaemia	and	impaired	glucose	tolerance	(211).	Oral	testosterone	replacement	in	postmenopausal	women	has	shown	both	no	impact	on	insulin	sensitivity	(178)	and	small	reductions	in	insulin	mediated	glucose	disposal	(176).	
Studies	using	the	TTP	have	not	reported	any	effect	on	carbohydrate	metabolism,	usually	assessed	by	fasting	glucose	and	insulin	levels	(39,40,43,212).	In	a	pilot	study	investigating	the	effect	of	6	months	transdermal	testosterone	on	functional	capacity	and	insulin	resistance	in	36	elderly	women	with	cardiac	failure,	testosterone	was	associated	with	improved	exercise	tolerance,	muscle	strength	and	insulin	resistance	as	assessed	by	the	homeostasis	model	(213).	
The	complex	interplay	between	androgens,	estrogens,	SHBG	and	insulin	resistance	makes	data	interpretation	in	this	area	challenging.	As	with	androgen	levels	and	cardiovascular	disease,	it	appears	that	both	low	and	high	endogenous	androgen	may	adversely	affect	glucose	homeostasis.	In	keeping	with	this,	older	studies	involving	pharmacological	doses	have	suggested	a	detrimental	effect	from	exogenous	testosterone	however	studies	involving	physiological	doses	are	much	more	reassuring.	
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Data	involving	transdermal	replacement	are	encouraging	but	either	limited	to	basic	assessments	of	glucose	metabolism	or	involving	populations	outwith	the	usual	prescribing	range	for	PM	testosterone	use	and	therefore	further	studies	are	needed.	
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Assessment	of	cardiovascular	risk	via	surrogate	markers	
From	a	research	perspective,	the	gold	standard	for	investigating	CV	risk	is	using	CV	events	as	a	primary	outcome.	However,	this	is	often	not	feasible	as	it	requires	large-scale	RCTs	with	many	years	follow-up.	Therefore,	other	ways	of	assessing	cardiac	risk	have	been	identified	using	surrogate	markers	which	predict	future	CV	events.	
In	clinical	settings,	assessment	of	CV	risk	is	usually	done	using	traditional	CV	risk	factors	identified	from	the	Framingham	study	such	as	hypertension,	hypercholesterolaemia	and	obesity	(214)	(215).	Hypertension	is	one	of	the	most	important	risk	factors	for	CV	disease	in	women	but	requires	accurate	measurement	and	in	clinical	practice	often	goes	undiagnosed	(215).	Many	biochemical	markers	of	CV	risk	have	been	identified,	including	impaired	glucose	tolerance,	elevations	in	total	cholesterol,	triglycerides,	LDL,	lipoprotein	(a)	and	reduced	HDL	(215,216).	
Despite	their	widespread	use,	it	has	been	shown	that	these	traditional	risk	factors	do	not	correlate	as	well	for	women	as	for	men	and	subsequently	may	underestimate	risk	(217)((218).	Therefore	there	is	a	need	to	find	more	accurate	ways	to	predict	CV	risk,	particularly	in	women.	The	use	of	surrogate	markers,	or	methods	which	detect	subclinical	disease,	is	increasing	but	at	present	is	most	commonly	confined	to	research	settings.	
	 	
• Endothelial	function	
	
o Role	of	the	endothelium	
Control	of	vascular	tone	in	response	to	internal	and	external	stressors	is	an	essential	regulatory	function	within	the	CV	system.	This	may	be	mediated	by	the	actions	of	hormones	and	the	autonomic	nervous	system	on	vascular	smooth	muscle	or	may	be	influenced	by	local	cytokine	activation	at	the	endothelium.	
The	endothelium	is	increasingly	recognised	as	an	important	interface,	both	in	health	and	disease.		Vascular	injury,	and	subsequent	endothelial	dysfunction,	are	well	
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established	precursors	to	atherosclerosis	(219),	coronary	artery	disease	and	CV	events	(220,221).		
The	process	of	atherosclerosis	is	mediated	by	abnormalities	of	the	vascular	endothelium.	Injury	to	endothelial	cells	may	be	secondary	to	recognised	risk	factors	such	as	smoking,	diabetes	and	hypertension	but	aging	and	genetic	factors	are	also	important	(figure	3).	Cumulative	insults	to	the	endothelial	cells	result	in	decreased	NO	production,	increased	platelet	adhesion,	and	increased	expression	of	adhesion	molecules	which	lead	to	macrophage	binding	to	the	endothelial	surface.	In	the	presence	of	increased	pro-inflammatory	cytokines,	the	macrophages	migrate	into	the	vascular	wall	and	engulf	lipid	to	form	foam	cells.	Smooth	muscle	cells	migrate	into	the	vascular	intima	and	release	pro-thrombotic	cytokines	which	leads	to	the	characteristic	fibrous	cap	overlying	a	lipid	core	seen	in	advanced	atherosclerosis.	In	addition,	impaired	endothelial	cells	are	less	able	to	perform	fibrinolysis	and	produce	increased	quantities	of	vasoconstrictors	such	as	endothelin-1	and	angiotensin	2.	As	the	plaque	gradually	occludes	the	vessel,	angina	may	develop,	whereas	rupture	of	the	fibrous	plaque	with	subsequent	exposure	of	the	elements	to	the	blood	leads	to	acute	thrombosis	and	myocardial	infarction.	
A	crucial	feature	of	an	intact	endothelium	is	the	ability	to	vasodilate	in	response	to	NO.	Endothelial	dysfunction	is	characterised	by	a	reduction	in	bioavailability	of	NO	and	subsequent	reduction	in	endothelium	dependent	vasodilatation	(222).		NO	is	released	from	the	endothelium	in	response	to	stress	or	insults	and	has	several	important	anti-atherogenic	mechanisms	including	the	maintenance	of	normal	arterial	resting	tone,	as	well	as	the	inhibition	of	leucocyte	adhesion,	platelet	aggregation	and	smooth	muscle	cell	proliferation	(219).	Endothelial	dysfunction	is	therefore	associated	with	abnormal	vascular	tone	and	a	pro-thrombotic,	pro-inflammatory	environment	which	predisposes	to	atheroma	development	(120).		
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Figure	3.	Pathophysiology	of	atherosclerosis	
			
o Testing	endothelial	function	
Endothelial	function	can	be	tested	by	assessing	the	vasodilator	response	to	physiological	or	pharmacological	stimuli	known	to	induce	endothelial	release	of	NO	(223).	Many	methods	for	assessment	of	endothelial	function	have	been	identified	(224).	The	gold	standard	has	traditionally	been	assessment	of	coronary	artery	endothelial	function.	Coronary	artery	testing	requires	intra-arterial	administration	of	pharmacological	therapies	such	as	acetylcholine,	which	induce	production	of	endothelial	NO,	and	the	assessment	of	changes	in	artery	diameter	using	quantitative	coronary	artery	angiography.	The	invasive	nature	of	these	tests	has	limited	their	widespread	use	and	led	to	the	development	of	non-invasive	methods	to	assess	endothelial	function.	
Endothelial	dysfunction	is	a	systemic	process,	not	just	limited	to	coronary	circulation	and	so	non-invasive	techniques	to	measure	peripheral	artery	endothelial	function	have	been	developed.	This	is	most	commonly	done	by	flow	mediated	vasodilatation	(FMD)	of	the	brachial	artery	(225).	Brachial	artery	diameter	is	measured	by	ultrasound	before	and	after	reactive	hyperaemia	(RH),	which	stimulates	local	endothelial	release	of	NO.	This	technique	also	has	significant	limitations	including	the	requirement	for	specialist	training	particularly	in	sonography	(226)	and	expensive	equipment.	FMD	assessment	is	a	complex	technique,	and	is	therefore	susceptible	to	significant	operator	variability	(225).		
	 45	
o Peripheral	Arterial	Tonometry	(PAT)	
The	recognition	that	changes	in	pulse	wave	amplitude	can	be	measured	to	assess	endothelial	function	led	to	the	development	of	finger	plethysmography	to	record	pulse	wave	amplitude	via	peripheral	arterial	tonometry	(PAT)(227).	This	offers	a	simple,	non-invasive	technique	which	measures	digital	volume	changes	in	response	to	reactive	hyperaemia	(RH)	in	order	to	calculate	an	index	of	endothelial	function.	The	finger	probe	plethysmography	records	the	pulse	wave	volume	during	each	pulsation.	After	a	baseline	recording	a	blood	pressure	cuff	is	inflated	to	supra-systolic	pressures	for	5	minutes	(the	occlusion	phase)	and	then	released.	In	a	healthy	individual	the	pulse	wave	volume	will	increase	rapidly	whereas	a	muted	response	will	be	observed	in	individuals	with	endothelial	dysfunction	(figure	4).	From	the	recordings,	an	RH	index	(RHI)	is	calculated	as	the	ratio	of	average	amplitude	during	RH	compared	to	baseline.	Measurements	taken	in	the	contra-lateral	arm	are	used	as	control	data	to	take	into	account	the	systemic	non-endothelial	dependent	effects	of	RH.	
RHI	shows	good	correlation	with	CV	risk	factors	(228)	and	with	other	measurements	of	endothelial	function	(227,229).	Bonetti	et	al.	have	reported	that	an	RH-PAT	index	of	<1.35	has	a	80%	sensitivity	and	85%	specificity	to	identify	patients	with	coronary	endothelial	dysfunction	as	diagnosed	by	reduced	coronary	artery	vasodilatation	in	response	to	acetylcholine	infusion(229).	Kuvin	et	al.	(227)	found	a	linear	relationship	between	FMD	and	PAT-RHI	in	patients	presenting	with	chest	pain.	
Impaired	RH-PAT	indices	have	been	shown	to	predict	coronary	artery	disease	in	women	as	assessed	by	coronary	angiography	(230)	and	CV	events	(231).	In	a	sub-study	from	the	Kronos	Early	Estrogen	Prevention	Study,	PAT-RHI	was	used	in	recently	postmenopausal	healthy	women	where	it	was	shown	to	be	useful	tool	for	CV	risk	stratification	and	suggested	as	a	method	of	assessing	response	to	hormonal	therapy	(232).	A	literature	search	did	not	find	any	other	studies	which	have	used	RHI	to	assess	endothelial	response	to	hormone	therapy	in	women.	
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Figure	4.	Data	showing	recordings	from	PAT	showing	endothelial	response	in	
subjects	with	(a)	high	hyperaemic	response	and	(b)	reduced	hyperaemic	
response.	Reprinted	with	permission	from	reference	(233).	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
• Arterial	Stiffness	
In	addition	to	endothelial	function,	a	further	regulator	of	arterial	blood	flow	is	vascular	elasticity.	Arterial	stiffness	is	increased	in	those	with	coronary	artery	disease	(234,235)		and	is	a	predictor	of	risk	of	CV	events	(234,236)	and	has	therefore	been	used	as	a	surrogate	marker	to	assess	CV	risk.		An	estimate	of	arterial	stiffness	can	be	made	using	the	technique	of	pulse	wave	analysis	(PWA),	which	uses	radial	artery	applanation	tonometry	(Sphygmocor,	AtCor,	Sydney	Australia).	This	records	peripheral	pulse	waveforms	from	which	central	arterial	(usually	the	ascending	aorta)	waveforms	can	be	derived	using	a	transfer	function.	Analysis	of	the	aortic	waveform	can	then	be	used	to	derive	estimates	of	arterial	stiffness.	A	commonly	used	method	of	quantifying	a	surrogate	measure	of	arterial	stiffness	is	by	calculating	the	augmentation	index	(AIx).		
(a)	 (b)	
Occlusion	phase	
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The	arterial	pressure	waveform	achieves	it	characteristic	shape	from	a	combination	of	the	forward	pressure	wave	produced	by	ventricular	systole	and	the	pressure	from	a	reflected	wave	returning	from	the	peripheral	vasculature.	In	the	case	of	increased	arterial	stiffness,	the	pulse	wave	velocity	is	increased	and	so	the	pressure	from	the	reflected	wave	occurs	earlier	within	the	waveform.	This	can	be	quantified	by	the	Augmentation	Index	(AIx),	which	is	defined	as	the	difference	between	the	second	and	the	first	systolic	peaks	expressed	as	a	percentage	of	pulse	pressure	(figure	5).		
Although	several	methods	for	measuring	arterial	stiffness	exist	(237),	PWA	is	a	simple,	non-invasive	technique	which	has	shown	high	levels	of	repeatability	(238).	Changes	in	AIx	have	been	used	in	many	studies	to	assess	the	effect	of	pharmacological	interventions	(239),	including	HT	studies	(240).	Furthermore,	assessment	of	the	changes	in	AIx	in	response	to	GTN	and	salbutamol	can	assess	endothelial	dependent	and	independent	vasodilatation	and	so	can	be	used	as	a	further	measure	of	endothelial	function	(241).	
There	are	no	prior	studies	which	have	used	AIx	to	assess	the	effect	of	postmenopausal	testosterone.	However	studies	have	used	AIx	to	assess	the	effect	of	testosterone	replacement	in	men	(242)	and	estrogen	replacement	in	women	(243)	over	similar	time	periods	(3-4	months).	
Figure	5:	Representation	of	the	arterial	waveform	and	calculation	of	
Augmentation	Index	(AIx).	SBP	systolic	blood	pressure,	DBP	diastolic	blood	pressure.	Modified	from	(237,239)
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SUMMARY	OF	LITERATURE	REVIEW	
	Androgens	play	a	crucial	role	in	female	physiology,	however	their	exact	role	is	poorly	understood.	They	may	act	directly	via	the	androgen	receptor,	which	is	found	in	many	tissues,	or	indirectly,	through	conversion	to	estradiol	in	peripheral	tissues.		Androgen	levels	decline	gradually	with	age	and	surgical	menopause	is	associated	with	a	40-50%	fall	in	testosterone	levels.	Androgen	deficiency	has	been	particularly	associated	with	reduced	sexual	desire	and	testosterone	is	increasingly	used	as	part	of	hormone	replacement	regimens.	There	are	data	showing	significant	benefit	from	postmenopausal	testosterone	replacement	in	terms	of	sexual	function,	well-being,	quality	of	life,	cognitive	function	and	bone	density.	Despite	the	well-documented	benefits,	safety	concerns	exist,	particularly	regarding	the	lack	of	long-term	safety	data.	
Theoretical	concerns	about	the	increased	risk	of	endometrial	or	breast	cancer	have	been	raised	due	to	peripheral	conversion	of	testosterone	to	estradiol.	There	are	a	lack	of	long-term	RCTs	with	these	conditions	as	primary	outcomes	however	current	data	do	not	point	to	an	increased	risk	of	breast	or	endometrial	cancer	from	testosterone	replacement.	
Of	greater	concern	are	the	potential	CV	effects	of	testosterone	as	it	has	traditionally	been	assumed	that	androgens	have	a	detrimental	effect	on	the	CV	system.	However,	recent	data	have	highlighted	the	complexities	of	the	CV	effects	of	testosterone.	At	present,	epidemiological	data	appears	to	point	to	a	U-shaped	association	between	endogenous	testosterone	levels	and	cardiovascular	disease.	The	implications	of	these	findings	for	postmenopausal	use	of	testosterone	are	not	well	understood.	
Although	older	studies	of	testosterone	replacement	pointed	to	detrimental	effects	on	lipid	profile	and	surrogate	markers	for	CV	risk,	these	studies	involved	high	dose	parenteral	treatment.	As	with	estrogen	replacement	there	has	been	a	move	towards	low	dose,	physiological	hormone	replacement	via	the	transdermal	route.	Few	studies	have	investigated	the	CV	effects	of	postmenopausal	testosterone,	particularly	via	the	transdermal	route.	Available	data	point	to	no	adverse	effect	from	physiological	testosterone	replacement	on	risk	factors	for	CV	disease	such	as	blood	pressure,	lipid	metabolism	or	fat	distribution.		
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There	are	no	studies	investigating	the	effects	of	postmenopausal	testosterone	with	CV	events	as	a	primary	outcome.	Pooled	analysis	of	5	phase	3	safety	studies	showed	no	increase	in	CV	events	(192).	In	the	only	study	to	investigate	subcutaneous	testosterone	in	PM	women,	implant	therapy	was	associated	with	an	improvement	in	endothelial	function,	potentially	suggesting	a	beneficial	CV	effect	(186).	
A	further	important	marker	of	CV	risk	is	impaired	glucose	metabolism.	Older	studies	using	high	dose	parenteral	testosterone	have	suggested	a	detrimental	effect	from	androgens	on	glucose	metabolism.	Data	involving	transdermal	physiological	replacement	have	been	more	reassuring	but	have	been	limited	to	basic	assessment	of	insulin	resistance.	
A	summary	of	all	studies	identified	involving	transdermal	or	subcutaneous	testosterone	replacement	can	be	found	in	table	3.	
	
Assessment	of	CV	risk	via	surrogate	markers	
Although	a	RCT	with	CV	events	as	a	primary	endpoint	would	be	considered	the	gold	standard	for	assessing	the	CV	effect	of	postmenopausal	testosterone,	this	approach	has	inherent	disadvantages,	particularly	the	need	for	large-scale	long-term	follow-up.	Surrogate	markers	for	CVD	are	therefore	frequently	used	as	a	more	practical	alternative.	
The	traditional	risk	factors	for	CVD,	such	as	blood	pressure	and	lipid	profile,	do	not	predict	CV	events	as	accurately	in	women	as	in	men.	Many	other	surrogate	markers	for	CVD	have	been	identified	including	measures	of	endothelial	function	and	arterial	stiffness,	both	of	which	have	been	shown	to	correlate	well	with	future	CV	events.		
Simple	non-invasive	methods	of	measuring	endothelial	function	and	arterial	stiffness	have	been	developed	which	correlate	well	with	the	gold	standard	techniques.	The	techniques	used	in	the	present	study	for	assessing	arterial	stiffness	(radial	artery	applanantion	tonometry,	Sphygmocor)	and	endothelial	function	(peripheral	artery	tonometry,	Endopat)	have	not	previously	been	used	to	assess	the	effect	of	
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postmenopausal	testosterone	replacement	but	have	been	used	to	assess	the	effect	of	other	hormonal	therapies	in	both	men	and	women.		 	
Table	3.	Summary	of	studies	of	exogenous	transdermal/subcutaneous	testosterone	replacement	
	
Author	(year)	 Study	type	 Population	 Primary	route	of	T	treatment	 Primary	outcome	 Ref.	
	 	 	 	 	 	
Patch	 	 	 	 	 	Braunstein	(2005)	 RCT	 447	SM	on	E	 TTP	24	weeks	150/300/450μg	doses	 Increased	sexual	activity	and	desire	(PFSF)	in	300ug	dose	 41	Buster	(2005)	 RCT	 533	SM	on	E	 TTP	24	weeks	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	 42	Davis	(2006)	 RCT	 77	SM	on	E	 TTP	24	weeks	 Improved	sexual	desire	on	PFSF	 38	Davis	(2008)	 RCT	 814	NM	and	SM,	not	on	HT	 TTP	24	weeks	150/300μg	doses	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	for	300μg	dose	 43	Davis	(2009)	 Retrospective	cohort	 631	PM	women	 Transdermal	or	implant	 No	increased	risk	breast	cancer.	RR	1.35	(95%	CI	0.76-2.38)	 86	Davis	(2009b)	 RCT	 279,	no	HT	 TTP	24	weeks	150/300μg	doses	 No	effect	on	mammographic	density	 89	Fooladi	(2014)	 RCT	 44	pre	and	PM	women	with	SSRI/SNRI-emergent	loss	of	libido	 TTP	12	weeks	 Increased	satisfactory	sexual	events	 56	Hofling	(2007a+b)	 RCT	 99	PM	on	CEE/NET	 TTP	24	weeks	 Reduction	in	breast	cell	proliferation,	no	effect	on	mammographic	density	 87,	88	Iellamo	(2010)	 RCT	 36	older	PM	with	heart	failure	 TTP	24	weeks	 Improved	functional	capacity,	insulin	resistance	and	muscle	strength	 213	Panay	(2010)	 RCT	 272	NM,	mainly	not	on	HT	 TTP	24	weeks	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	 55	
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Popat	(2014)	 RCT	 145	POI	 TTP	12	weeks	150μg	 No	additional	benefit	from	T	at	12	weeks	but	projected	benefit	at	3	years	using	repeated	measures	model	 71	Shifren	(2000)	 RCT	 75	SM	on	CE	 TTP	12	weeks	150/300μg	doses	 Increased	sexual	activity	and	pleasure-orgasm	and	psychological	well-being	 54	Shifren	(2006)	 RCT	 549	NM	on	HT	 TTP	24	weeks	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	 39	Simon	(2005)	 RCT	 562	SM	on	E	 TTP	24	weeks	 Increased	sexual	activity	(x2	episodes/wk)	and	desire	(PFSF),	reduced	distress	 40	Vitale	(2008)	 Pooled	analysis	on	5	RCTs	 2795	NM	and	SM,	with	and	without	HT	 TTP	24-52	weeks	 No	effect	on	CV	events	or	risk	factors	(lipids,	insulin,	glucose,	BP),	except	reduction	in	HDL	increases)	 192		 	 	 	 	 	
Gel/cream	 	 	 	 	 	Davis	(2014)	 RCT	 92	PM	women,	no	HT	 Transdermal	gel,	300ug	daily	26	weeks	 Improved	verbal	learning	and	memory	 66	Gruber	(1998)	 RCT	 39	NM	women	not	on	HT	 Transdermal	gel,	24	weeks	 Reduction	in	BMI,	total	body	weight	and	abdominal	fat	 179	Nathorst-Boos	(2006)	 RCT,	cross	over	 53	PM	on	HT	 Transdermal	gel,	10mg	daily,	24	weeks	 Increased	sexual	activity,	desire,	orgasm	and	arousal.	Improved	psychological	well-being.	 57	Shah	(2006)	 RCT	 76	PM	on	E	 Transdermal	gel,	400muL	daily	16	weeks	 Improved	immediate	and	delayed	visual	and	verbal	memory,	unaffected	by	AI	 65		 	 	 	 	 	
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White	(2012)	 RCT	 3-4000	 Transdermal	gel,	0.22g/d,	>12	months	 Composite	of	CV	events	-	results	not	yet	reported.	 193	Witherby	(2011)	 Open	label	pilot	 21	PM	women	with	BC	and	AI	induced	vaginal	atrophy	 Vaginal	cream	300/150μg	doses	daily	for	4	weeks	 Improvement	on	dyspareunia,	dryness,	vaginal	pH	and	maturation	index	with	300ug	dose	 59	
	 	 	 	 	 	
Implant	 	 	 	 	 	Burger	(1987)	 RCT	 22	PM	 T	50mg	implant,	6	weeks	 Improved	libido	 51	Cardozo	(1984)	 Observational	 120	PM	 E(50mg)	+	T(100mg)	implants	 Improved	vasomotor	symptoms,	libido	and	mood	 50	Davis	(1995)	 RCT	 34	PM,	on	E	 T	implant	50mg	3-monthly	24	months	 Improvement	in	bone	density	and	sexual	function	 67	Davis	(2000)	 RCT	 33	PM	on	HT	 50mg	T	implants	every	3	months	2	years	 Increased	lean	body	mass	 177	Dimitrakakis	(2004)	 Retrospective	observational	 508	PM	 T	Implants	5-150mg,	5monthly	 No	increased	rates	of	breast	cancer.	Incident	rates	E+T	115/100,000,	E/P+T	293/100,000	 83	Garnett	(1992)	 RCT	 50	PM	on	E	 T	implant	100mg	6-monthly	for	12	months	 No	increase	in	bone	density	c/t	E	alone	 70	Glaser	(2011)	 Cohort	study	 300	pre-	and	PM,	no	HT	 T	implant	75-160mg	 Improvement	in	psychological,	somatic	and	urogenital	symptoms	 33	Van	Staa	(2009)	 Observational	case-control	 2103	T	users,	6309	controls	 Implant	(72.2%),	oral	(18.4%),	IM	(7.9%)	 No	increased	risk	of	breast	cancer.	RR	breast	cancer	0.78	(95%	CI	0.44-1.37)	 81	Worboys	(2001)	 Case-control	 33	PM	women	on	HT	 T	implant	50mg	6	weeks	 Improvement	in	endothelium	dependent	and	independent	vasodilation	 186	
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AI	aromatase	inhibitor,	BC	breast	cancer,	BP	blood	pressure,	CEE	conjugated	equine	estrogens,	CI	confidence	interval,	CV	cardiovascular,	E	estrogen,	HDL	high	density	lipoprotein,	HT	hormone	therapy,	IM	intramuscular,	NM	naturally	menopausal,	NET	norethisterone,	PFSF	profile	of	female	sexual	function,	PM	postmenopausal,	POI	premature	ovarian	insufficiency,	RCT	randomised	controlled	trial,	RR	relative	risk,	SM	surgically	menopausal	T	testosterone,	TTP	transdermal	testosterone	patch.
STUDY	AIMS	AND	OUTCOME	MEASURES		
The	present	study	aimed	to	investigate	the	effect	of	the	TTP	on	CV	health	and	libido.	
The	primary	outcome	measures	were	defined	as	changes	in	arterial	stiffness	(AIx,),	endothelial	function	(AIx	in	response	to	GTN	and	salbutamol,	and	RHI)	and	insulin	resistance	(HOMA-IR).		
Secondary	outcome	measures	were	defined	as	changes	in	sexual	function	(B-PFSF),	blood	pressure,	body	composition	(weight,	BMI,	waist	and	hip	circumference),	and	lipid	metabolism	(total	cholesterol,	HDL	cholesterol,	lipoprotein	(a)).	
	
HYPOTHESES	
• Transdermal	testosterone,	in	conjunction	with	HRT,	will	not	have	adverse	effect	on	insulin	resistance	or	vascular	function	in	postmenopausal	women.	
• Transdermal	testosterone	will	significantly	improve	sexual	well-being	in	postmenopausal	women.	
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METHODOLOGY	
	
Trial	participants	
The	study	was	approved	by	the	West	London	Research	Ethics	Committee,	UK	medicines	regulatory	authorities	(MHRA)	and	NHS	trusts.	It	was	registered	with	the	National	Agency	for	Medicine	(EudraCT	2009-013275-21).	The	study	was	conducted	according	to	the	principles	of	the	Declaration	of	Helsinki	and	Good	Clinical	Practice.	All	participants	gave	written	informed	consent	prior	to	any	study	procedures.		
Subjects	were	recruited	from	hospital	endocrinology/menopause	clinics	between	February	2011	and	November	2011	and	all	study	visits	took	place	at	the	Royal	Brompton	NHS	Foundation	Trust,	London.	Participants	were	healthy	menopausal	women	aged	between	45-70	years,	on	a	stable	HT	regimen	and	complaining	of	symptoms	of	low	libido.	Women	with	a	history	of	recent	testosterone	use	(<3	months	transdermal	or	<12	months	subcutaneous)	were	excluded.		
Other	exclusion	criteria	included	dyspareunia,	medications	which	may	interfere	with	the	study	(Selective	Serotonin	Reuptake	Inhibitors	(SSRIs),	anti-androgens,	Phosphodiesterase	type	5	(PDE5)	inhibitors,	dihydroepiandrosterone	(DHEA),	selective	estrogen	receptor	modulators	(SERMS)),	current	warfarin	use,	significant	psychiatric	co-morbidity,	history	of	breast	cancer,	diabetes	mellitus,	thrombo-embolic	disorders,	cardiovascular	disease,	any	condition	affecting	carbohydrate	metabolism,	uncontrolled	hypertension	and	uncontrolled	hyperlipidaemia,	current	use	of	tibolone	(due	to	its	androgenic	effect)	or	hypersensitivity	to	testosterone	(table	4).	
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Table	4.	Study	exclusion	criteria.	
	
Exclusion	criteria	Dyspareunia	Medications	which	may	interfere	with	the	study							SSRIs,	anti-androgens,	PDE5	inhibitors,	DHEA,	SERMS,	tibolone	Current	use	of	warfarin	Significant	psychiatric	co-morbidity	History	of	medical	co-morbidities:	
• breast	cancer																																					diabetes	mellitus		
• thrombo-embolic	disorders										cardiovascular	disease	
• uncontrolled	hypertension												uncontrolled	hyperlipidaemia		
• any	condition	affecting	carbohydrate	metabolism		Hypersensitivity	to	testosterone			
Following	the	baseline	visit,	participants	received	the	300mcg	transdermal	testosterone	patch	(Intrinsa®,	Warner	Chilcott)	for	12	weeks,	with	study	visits	after	6	weeks	and	12	weeks	of	testosterone	use.	The	TTP	is	worn	on	the	abdomen	and	patches	are	replaced	every	3.5	days.		
Visits	were	performed	in	a	temperature	and	noise	controlled	environment	at	the	same	time	of	day.	Subjects	were	fasted	for	12	hours	prior	to	visits	and	were	asked	to	abstain	from	caffeine	or	alcohol	for	6	hours	prior	to	study	visits.	Measurements	of	endothelial	function	and	arterial	stiffness	were	performed	prior	to	blood	samples	and	anthropometric	measurements.	All	participants	had	a	normal	physical,	pelvic	and	breast	examination	at	baseline	visit.	All	study	assessments	were	carried	out	by	one	investigator	to	avoid	inter-observer	variability.	Full	details	of	investigations	carried	out	at	each	visit	can	be	seen	in	table	5.	
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Table	5.	Details	of	procedures	undertaken	at	each	study	visit.	
	
	
Procedure	
Visit	1																					
(Start)	
Visit	2	
(Week	6)	
Visit	2	
(Week	
12)	Measurement	 of	 blood	 pressure,	 temperature,	heart	 rate,	 weight,	 waist	 and	 hip	 measurements,	height	1.	 ü	 ü	 ü	Demographic	data	recorded.	 ü	 	 	Medical	and	gynaecological	history.		 ü	 	 	Examination	of	facial	and	scalp	hair,	acne	and	voice	depth.	 ü	 ü	 ü	Physical	 examination	 including	 breast	 and	 pelvic	examination.	 ü	 	 	Hormone	profile	and	lipid	profile.	 ü	 ü	 ü	Liver	function	test	and	full	blood	count	 ü	 ü	 ü	Fasting	glucose	and	insulin.	 ü	 ü	 ü	Arterial	compliance	measurements.	 ü	 	 ü	Endothelial	function	assessment	 ü	 	 ü	BPFSF	completed	.	 ü	 ü	 ü	General	 assessment	 of	 well-being.	 	 Asked	 about	any	current	medication	and	any	side	effects.	 	 ü	 ü	Dispensing	of	patches.		 ü	 	 	Return	unused	patches.	 	 	 ü	
	1	Only	on	Visit	1.			
Radial	artery	applanation	tonometry	
	KM	performed	all	measurements,	which	were	undertaken	in	a	quiet,	temperature-controlled	room.	Blood	pressure	was	measured	at	the	brachial	artery,	in	the	supine	position	of	the	contra-lateral	arm	being	used	for	using	for	assessment	of	vascular	function,	after	a	10	minute	rest.		
Peripheral	pressure	waveforms	were	captured	using	radial	artery	applanation	tonometry	via	the	SphygmoCor	apparatus	(AtCor	Medical	Ltd.,	Sydney,	Australia;	software	version	8.0).	The	central	(ascending	aortic)	pressure	waveform	was	then	
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derived	from	an	averaged	peripheral	waveform	using	a	validated,	transfer	function	(244).	The	augmentation	index	(AIx),	which	gives	a	composite	measure	of	wave	reflection	and	systemic	arterial	stiffness	can	then	be	calculated	by	analysis	of	the	central	waveform.	AIx	was	defined	as	the	difference	between	the	first	and	second	systolic	peaks	of	the	central	pressure	waveform,	expressed	as	a	percentage	of	the	central	pulse	pressure.	Only	measurements	which	achieved	a	quality	index	of	90%	or	greater	were	included	in	the	analysis.	Baseline	measurements	were	repeated	and	an	average	of	3	measurements	taken.	As	AIx	is	dependent	on	heart	rate,	it	was	normalized	to	a	heart	rate	of	75	beats	per	minute	for	comparisons.	
Pulse	wave	analysis	was	also	used	to	assess	endothelial	function.	This	was	carried	out	by	assessing	the	changes	in	AIx	in	response	to	glyceryl	trinitrate	(GTN),	an	endothelium-independent	vasodilator,	and	salbutamol,	an	endothelium-dependent	β2-adrenoceptor	agonist,	using	a	validated	method	(242).	Endothelial	dysfunction	is	characterized	by	attenuation	of	endothelium-dependent	vasodilatation.	
Subjects	were	given	sublingual	GTN	(250	µg)	and	recordings	for	AIx	were	taken	from	baseline	to	20	minutes	post	administration.	Following	a	30	minute	washout	period,	salbutamol	400µg	was	given	by	supervised	inhalation	(Ventolin	Rotacap,	Allen	&	Hanbury’s,	Uxbridge,	United	Kingdom)	after	initial	demonstration.	The	empty	cap	was	inspected	after	each	inhalation	to	ensure	complete	drug	delivery.	AIx	measurements	were	then	recorded	again	from	baseline	to	20	minutes	after	inhalation.	The	response	to	salbutamol	or	GTN	was	defined	as	the	maximum	change	in	AIx	after	drug	administration	as	per	previous	studies	(245,246).	An	endothelial	function	index	was	then	calculated,	expressing	endothelium-dependent	vasodilatation	(salbutamol)	as	a	percentage	of	endothelium-independent	vasodilatation	(GTN).	
	
RH-PAT	
	
Endothelial	function	was	further	assessed	by	measuring	digital	pulse	volume	changes	in	response	to	reactive	hyperaemia,	using	PAT	technology	(EndoPAT®	2000,	Itamar	Medical	Ltd,	Israel).	KM	performed	all	measurements	in	a	quiet,	temperature	controlled	
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environment	with	subjects	in	fasted	state.	The	RH-PAT	technique	was	carried	out	as	described	in	prior	studies	(229,247).		
Subjects	lay	in	a	supine	position	and	a	PAT	finger	probe	was	placed	on	each	index	finger	with	both	hands	at	the	same	level	(figure	6).	Finger	probes	consist	of	inflatable	latex	air-cushions	within	a	rigid	cover	which	apply	constant	counter	pressure	to	the	fingertip.	Volume	changes	were	detected	by	a	pressure	transducer	and	transferred	to	computer.		A	blood	pressure	cuff	was	placed	on	one	upper	arm	while	the	other	arm	acted	as	the	control	arm.	After	an	initial	stabilisation	period,	a	baseline	measurement	was	taken	for	at	least	5	minutes,	followed	by	a	5	minute	occlusion	period,	where	a	blood	pressure	cuff	was	inflated	to	60mmHg	above	the	systolic	blood	pressure.	After	cuff	release,	post-occlusion	monitoring	continued	for	a	further	5	minutes.	From	the	data,	the	Reactive	Hyperaemia	Index	(RHI)	was	calculated	automatically	by	the	EndoPAT	2000	computer	algorithm	from	the	ratio	of	pulse	wave	amplitude	before	and	after	ischaemia,	compared	to	the	control	arm.	A	lower	RHI	was	indicative	of	endothelial	dysfunction.	
	
Figure	6.	Representation	of	the	Endopat	finger	probes	and	study	set-up.	Reprinted	with	permission	from	reference	(233).		
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Glucose	metabolism	and	HOMA-IR	
	Blood	samples	were	taken	for	fasting	glucose	and	insulin	levels.	From	these	results,	insulin	resistance	was	then	estimated	using	the	updated	homeostasis	model	assessment	method	for	insulin	resistance	(HOMA-IR)	computer	algorithm	(248,249).	
The	HOMA-IR	model,	first	described	in	1985	(250),	uses	fasting	glucose	and	insulin	concentrations	to	derive	a	surrogate	index	of	insulin	resistance.	It	has	been	shown	to	correlate	well	with	the	more	invasive	gold	standard	technique	for	assessing	insulin	resistance	–	the	hyperinsulinaemic	euglycaemic	glucose	clamp	method	(249).	The	hyperinsulinaemic	euglycaemic	clamp	method	requires	insertion	of	2	intravenous	catheters,	trained	staff	and	is	time	consuming	(251).	Several	other	methods	of	assessing	insulin	sensitivity	exist	(252)	but	the	HOMA-IR	model	provides	an	easy,	inexpensive	tool	by	which	to	assess	longitudinal	changes	to	IR	in	a	clinical	trial	setting.	
			
Hormone,	biochemical	and	haematological	parameters	
	All	blood	samples	were	performed	in	a	fasted	state.		
Hormones,	including	testosterone,	were	measured	by	an	electro-chemiluminescent	assay	(Roche	Diagnostics	Ltd,	Burgess	Hill,	UK).	Inter-	and	intra-assay	percentage	coefficients	of	variation	were	<5%	for	testosterone,	<5%	for	insulin,	<7%	for	estradiol	and	<4%	for	SHBG.	Free	androgen	index	(FAI)	was	calculated	using	the	equation:	FAI	=	(testosterone	(nmol/l)/SHBG	(nmol/l))	x	100.		
Total	cholesterol,	HDL	cholesterol	and	liver	function	tests	were	assayed	using	a	Beckman	DxC600	analyser	(Beckman	Coulter,	High	Wycombe,	Bucks,	UK)	and	lipoprotein	(a)	on	a	Beckman	Immage	nephelometer	(Beckman	Coulter,	High	Wycombe,	Bucks,	UK).	
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Assessment	of	female	sexual	function	 
	Libido	was	assessed	at	each	visit	using	the	Brief	profile	of	female	sexual	function	(B-PFSF),	a	validated	self-administered	questionnaire	(253)	for	identifying	HSDD.	The	B-PFSF	is	based	on	7	questions	(see	table	6).	Each	question	is	scored	on	a	6-point	scale	from	‘always’	to	‘never’.	A	total	score	is	calculated	from	a	sum	of	all	questions.	Previous	studies	have	identified	a	score	of	less	than	20	as	suggestive	of	HSDD	(253).	
	
Table	6.	The	brief	profile	of	female	sexual	function	questionnaire		 Never	 Seldom	 Sometimes	 Often	 Very	often	 Always	I	felt	like	having	sex	 0	 1	 2	 3	 4	 5	I	was	unhappy	about	my	lack	of	interest	in	sex	 5	 4	 3	 2	 1	 0	Getting	aroused	took	forever	 5	 4	 3	 2	 1	 0	I	felt	sexually	numb	 5	 4	 3	 2	 1	 0	I	lacked	sexual	desire	 5	 4	 3	 2	 1	 0	I	felt	disappointed	by	my	lack	of	interest	in	sex	 5	 4	 3	 2	 1	 0	I	reached	orgasm	easily	 0	 1	 2	 3	 4	 5	
	
	
Anthropometric	measurements	and	adverse	events	
	Anthropometric	measurements	were	performed	in	light	clothing	without	shoes.	Waist	circumference	was	measured	to	the	nearest	0.5	centimetres	(cm)	with	a	tape	measure	placed	at	the	midpoint	between	the	lower	margin	of	the	last	palpable	rib	and	the	iliac	crest,	as	per	World	Health	Organisation	(WHO)	guidance	(254).	Hip	circumference	was	measured	to	the	nearest	0.5cm	at	the	maximal	circumference	over	the	buttocks	with	the	
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tape	parallel	to	the	floor.	Weight	was	measured	in	light	clothing	to	the	nearest	0.1kilograms	(kg)	on	a	digital	scale.		Height	was	measured	to	the	nearest	centimetre	using	a	wall-mounted	stadiometer.	Body	mass	index	was	calculated	as	weight	(kg)	divided	by	height	(m)	squared.	
At	each	visit	an	assessment	of	adverse	effects	and	androgenic	side	effects	was	performed.	Facial	acne	was	graded	using	the	Palatsi	scale	from	0	(none)	to	4	(severe	acne)(appendix	1).	Assessment	of	facial	hirsutism	was	performed	using	the	Lorenzo	Scale	(appendix	2)	with	grades	0	(no	hair)	to	4	(heavy	hair	growth)	at	the	upper	lip	and	chin.	Subjects	were	questioned	as	to	whether	they	had	noticed	any	changes	in	their	voice,	patch	site	reactions,	unscheduled	bleeding	or	other	adverse	events.	
	
Validation	of	data	
• Arterial	Stiffness	
PWA	using	radial	artery	applanation	tonometry	is	operator	dependent,	although	previous	studies	have	shown	high	levels	of	intra-	and	inter-observer	repeatability,	even	in	those	with	limited	experience	(238)	
As	one	investigator	performed	all	measurements,	no	assessment	of	inter-observer	variability	was	performed.	Intra-observer	variability	was	assessed	by	performing	repeated	AIx	measurements	on	5	healthy	controls,	prior	to	subject	recruitment,	and	compared	to	previously	reported	results.	The	mean	difference	±	SD	between	repeated	AIx	measurements	was	0.3	±	0.8	(figure	7)	and	coefficient	of	variation	21.05%.		
This	compared	favourably	to	previous	studies	where	intra-observer	variability	of	0.1±8	(238),	1.5±7.0	(255),	and	1.5	±	1.1	(256)	have	been	observed.	
• RH-PAT	
EndoPAT	measurements	are	analysed	by	a	computerized	automated	algorithm	in	an	operator	independent	manner	and	therefore	inter-observer	variability	is	minimal	
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(233).	Prior	studies	have	confirmed	a	high	repeatability	of	EndoPAT	measurements,	with	repeat	testing	on	two	days	showing	high	correlation	under	controlled	conditions	(257,258).	
	
	
Figure	7.	Bland-Altman	plot	of	AIx	repeatability	data.	The	difference	between	paired	AIx	measurements	is	plotted	against	their	average.	The	mean	difference	and	2	standard	deviations	are	marked	
	
	
	
Statistical	Analyses	Plan	
• Sample	Size	Calculation	
There	were	a	lack	of	previous	data	on	which	to	base	accurate	power	calculations.	No	previous	studies	had	examined	the	effect	of	testosterone	replacement	in	women	using	AIx	or	RHI.	A	pilot	study	investigating	the	effect	of	3	months	of	transdermal	testosterone	gel	in	hypogonadal	men	on	AIx	found	no	significant	change	(242).	The	
Difference	between	AIx	measurements	
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present	study	was	therefore	designed	to	provide	data	to	aid	power	calculations	for	future	studies.		
Sample	size	calculations	estimated	that	recruitment	of	18	participants	into	the	study	would	provide	over	80%	power	to	detect	a	shift	of	1	standard	deviation	at	the	5%	level.	These	calculations	were	based	on	data	from	McEniery	et	al.	(255)	who	showed	a	mean	AIx	±	standard	deviation	of	33	±	9	in	495	50-59	year	old	women	and	Kuvin	et	al.	(227)	who	demonstrated	mean	RHI	of	1.6	±	0.2	in	20	postmenopausal	women.	We	therefore	aimed	to	recruit	at	least	20	subjects	to	allow	for	possible	dropouts.	
• Data	analysis	
Analyses	of	efficacy	and	safety	data	were	performed	after	all	participants	had	completed	their	last	visit.	
Analysis	was	performed	using	SPSS	v20.0.	All	demographic	data	have	been	summarised	for	the	participants.	For	categorical	variables,	the	number	and	percent	of	patients	in	each	category	is	presented.	Continuous	variables	such	as	age,	hormone	levels	and	vascular	assessments	are	summarised	by	presenting	the	sample	size,	mean	and	standard	deviation	or	median	and	range.	
Baseline	and	post	treatment	outcomes	have	been	compared	by	paired	Student’s	t	tests	on	normalised	data	or	Wilcoxon’s	signed	rank	test	for	non-parametric	comparisons.	Inter-dependencies	between	variables,	for	example	the	association	between	age,	body	mass	index	(BMI),	hormone	levels,	lipids,	AIx	and	RHI,	were	explored	using	Spearman’s	linear	correlation	analysis	(for	non-parametric	data)	or	Pearson’s	correlation	analysis	(parametric	data)	and	linear	regression	analysis.	For	the	primary	outcomes	(AIx	and	RHI)	p<	0.05	was	considered	statistically	significant.	
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RESULTS	
	
Baseline	Characteristics	
22	subjects	were	recruited	in	to	the	study.	One	subject	withdrew	consent	following	the	first	visit	and	did	not	commence	treatment.	21	subjects	completed	the	study.	The	data	presented	are	therefore	based	on	analysis	of	21	subjects	unless	otherwise	stated.	
The	baseline	characteristics	of	subjects	are	presented	in	Table	7.	No	subjects	were	currently	using	anti-hypertensives.	One	subject	was	using	a	lipid-lowering	agent	and	one	was	a	current	smoker	of	15-20	cigarettes	per	day.		
Mean	BMI	was	within	the	normal	range	based	on	WHO	classification.	Mean	baseline	HOMA-IR	was	0.78	(range	0.4-1.6)	with	only	4	subjects	having	a	very	mild	impairment	of	insulin	sensitivity.	
Although	symptoms	of	low	libido	were	required	to	participate	in	the	study,	based	on	the	B-PFSF	scores,	one	third	of	subjects	did	not	fulfil	the	diagnostic	criteria	for	HSDD	(usually	considered	to	be	a	score	<20).		
Baseline	arterial	stiffness	and	endothelial	function	compared	similarly	to	data	in	age	matched	populations.	McIneiry	et	al.		(255)	have	previously	demonstrated	a	mean	AIx	of	33±9	in	495	50-59	year	old	women.	Kuvin	et	al.	(227)	have	shown	a	mean	RHI	of	1.7±0.1	in	35	women	with	a	mean	age	of	53	years.	
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Table	7.	Clinical	and	demographic	characteristics	of	participants	at	baseline	
(n=21).	Values	are	expressed	as	mean	(SD)	or	median	(range).	
Characteristic	 	 Value	Age	(years)	 	 53.0	(6.7)	Smokers	(n)	 	 1	(4.8%)	Weight	(kg)	 	 68.2	(11.1)	BMI	(kg/m2)	 	 24.5	(4.7)	Waist	circumference	(cm)	 85.6	(11.4)	Hip	circumference	(cm)	 101.6	(8.5)	SBP	(mmHg)	 	 114.6	(11.8)	DBP	(mmHg)	 	 73.2	(9.5)	B-PFSF	 	 15.3	(9.1),	15	(0-33)	Estradiol	(pmol/L)	 	 332.0	(296.0)	Testosterone	(nmol/L)	 	 0.39	(0.31)	SHBG	(nmol/L)	 	 76.0	(36.3)	FAI	 	 0.56	(0.40)	Insulin	(pmol/L)	 	 40.38	(24.62)	Glucose(mmol/L)	 	 5.05	(0.66)	HOMA-IR	 	 0.78	(0.40)	Total	cholesterol	(mmol/L)	 5.65(0.79)	HDL	(mmol/L)	 	 1.83	(0.59)	Tot	chol:HDL	 	 3.31	(0.96)	Lipoprotein(a)	(mg/dL)	 	 29.9	(41.9)	RHI	 	 1.79	(0.36)	AIx	(%)	 	 24.21	(10.70)	Fall	in	AIx	after	GTN		 -18.55	(6.3)	Fall	in	AIx	after	salbutamol		 -2.9	(5.2)	Endothelial	function	index	 14.43	(29.82)		
	
• HT	preparations		
A	summary	of	the	HT	preparations	used	by	subjects	can	be	seen	in	table	8.	No	patients	were	using	CEE.	Of	the	21	patients	included	for	analysis,	five	were	using	estradiol	alone	due	to	prior	hysterectomy	(three	using	estradiol	transdermal	patch,	two	using	estradiol	implant).	Of	those	using	combined	EP	HT	this	was	mainly	transdermal	estradiol	(gel	or	patch)	with	the	levonorgestrel	intrauterine	system	(LNG-IUS)	(seven	patients)	or	
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micronized	progesterone	(six	patients).		Only	three	patients	were	using	other	progestogens	(Kliovance®	(oral	estradiol/NET),	Femseven	conti®	(transdermal	estradiol/LNG),	Elleste	duet®	(oral	estradiol/NET)).		Only	two	patients	were	using	oral	estradiol.	
	
Table	8.	Summary	of	HRT	preparations	used	by	subjects	
Type	of	HRT	preparation	
Estradiol	only	 	 Estradiol	+	progestogen	Transdermal									Subcutaneous						 3	2	 Transdermal	E2	+	levonorgestrel					8						Transdermal	E2	+	progesterone							6	Oral	E2	+	norethisterone																					2		
	
Impact	of	testosterone	on:	
• Sexual	function	
Compared	to	baseline	measurements,	scores	on	the	B-PFSF	questionnaire	improved	significantly	by	a	mean	of	3.7	points	by	6	weeks	(p<0.05)	and	5.05	points	by	12	weeks	(p<0.0001).	Significant	improvements	in	B-PFSF	score	were	also	seen	when	subjects	with	and	without	HSDD	were	analysed	separately	(table	9).	
There	was	no	correlation	observed	between	change	in	B-PFSF	score	and	changes	in	FAI,	total	testosterone	or	SHBG,	either	in	the	total	population,	or	when	the	subjects	with	HSDD	were	analysed	separately.		
Additionally,	there	was	no	correlation	between	baseline	B-PFSF	score	and	total	testosterone/FAI/SHBG.	However,	when	the	HSDD	group	was	analysed	separately	there	was	an	inverse	relationship	between	B-PFSF	score	and	total	testosterone	(r	0.56,	correlation	coefficient	(cc)	-0.665,	p<0.01)	but	not	FAI.	
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Figure	8.		Box	plot	showing	median	+	interquartile	range	for	B-PFSF	at	each	visit.	
	
	
	
	
	
Table	9.	Change	in	B-PFSF	in	subgroups	with	and	without	HSDD	
		 Mean	difference	in	B-PFSF		 95%	CI	 p	
HSDD	
(n=14)	 5.36	 1.9-8.8	 <0.05	
No	HSDD	
(n=7)	 4.43	 0.7-8.1	 <0.05	
	
	
	
	
B-PFSF	score	
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• Hormone	levels	
A	summary	of	the	observed	changes	in	various	serum	hormone	levels	can	be	seen	in	table	10.	These	results	show	that	12	weeks	of	transdermal	testosterone	resulted	in	significantly	increased	total	testosterone	(p<0.0001)	and	FAI	(p<0.001).	Levels	were	significantly	increased	by	6	weeks	of	testosterone	therapy	(p<0.001	for	both	total	testosterone	and	FAI).	No	significant	changes	were	observed	in	estradiol,	FSH	or	SHBG	levels.		
Table	10.	Change	in	serum	hormone	levels	following	12	weeks	of	testosterone	
therapy.	
		
Mean	difference	 95%	CI	 	 p	value	
FSH	(U/L)	 9.60	 	 -1.1	to	20.3	 0.077	
Estradiol	(pmol/L)	 -89.4	 	 -245.0	to	67.2	 0.349	
SHBG	(nmol/L)	 -5.50	 	 -16.5	to	5.5	 0.099	
Total	Testosterone	(nmol/L)	 1.26	 	 0.8	to	1.7	 <0.0001	
FAI	 2.04	 	 1.1	to	3.0	 	 <0.001	 	
	
• Anthropometric	and	metabolic	characteristics	
No	significant	change	was	observed	in	weight,	BMI	or	waist	circumference	over	the	duration	of	the	study.	Hip	circumference	significantly	reduced	(p<0.05).	No	changes	were	observed	in	systolic	or	diastolic	blood	pressure	(table	11).	
Although	total	cholesterol	and	total	cholesterol:HDL	ratio	were	unchanged,	there	was	a	small	but	significant	decrease	in	HDL	cholesterol	(p<0.05).	There	also	appeared	to	be	a	small	but	significant	reduction	in	lipoprotein	(a)	levels	(mean	difference	-3.11,	p<0.05)	
Fasting	glucose	and	insulin	measurements	were	used	to	derive	an	estimate	of	insulin	resistance	using	the	HOMA-IR.	No	changes	to	fasting	insulin,	fasting	glucose	or	insulin	resistance	were	observed.	
There	were	no	alterations	in	liver	enzymes	following	testosterone	therapy.	
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Table	11.	Effect	of	12	weeks	testosterone	therapy	on	anthropometric	and	
metabolic	characteristics.	
		
Mean	difference	 95%	CI	 	 p	value	
		 	 	 	 	 	
Weight	 0.443	 	 -0.18	to	1.07	 0.211	
BMI	 -0.159	 	 -0.38	to	0.07	 0.218	
Waist	Circumference	(cm)	 -0.262	 	 -1.38	to	0.86	 0.661	
Hip	Circumference	(cm)	 -0.738	 	 -1.42	to	-0.05	 <0.05	
Systolic	BP	 -2.52	 	 -7.02	to	1.98	 0.265	
Diastolic	BP	 1.81	 	 -2.80	to	6.42	 0.342	
Fasting	Glucose	(mmol/L)	 0.053	 	 -0.12	to	0.23	 0.533	
Fasting	Insulin	(pmol/L)	 5.809	 	 -10.66	to	22.27	 0.5	
HOMA-IR	 0.106	 	 -0.20	to	0.41	 0.705	
Total	cholesterol	(nmol/L)	 -0.0053	 	 -0.24	to	0.23	 0.964	
HDL	cholesterol	(mmol/L)	 -0.251	 	 -0.51	to	0.0071	 <0.05	
Total	chol:HDL	 -0.776	 	 -0.54	to	0.38	 0.689	
Lipoprotein	(a)	(mg/L)	 -3.11	 	 -76.32	to	13.75	 <0.05	
Bilirubin	(umol/L)	 -0.714	 	 -3.56	to	2.13	 0.888	
ALT	(IU/L)	 -0.619	 	 -6.90	to	5.66	 0.42			
	
• Endothelial	function	and	arterial	stiffness	
	
o Pulse	wave	analysis	
20	subjects	had	complete	arterial	stiffness	data	as	obtained	by	radial	artery	applanation	tonometry	and	were	therefore	included	in	the	analysis	as	presented	in	table	12.	There	was	no	difference	between	baseline	AIx	and	AIx	following	3	months	of	testosterone	therapy	(mean	difference	1.067,	95%	CI	-3.85	to	1.72,	p=0.433).	A	fall	in	AIx	was	noted	after	both	salbutamol	and	GTN	administration	and	there	was	a	significant	increase	in	salbutamol-mediated	vasodilatation	by	3	months	(p=0.029).		
Change	in	AIx	after	GTN	and	salbutamol	administration	was	used	to	derive	a	further	measure	of	endothelial	function	using	the	formula:	
EFI	=	AIx	before	salbutamol	administration	–	AIx	after	salbutamol	administration	x	100%										
										AIx	before	GTN	administration		–	AIx	after	GTN	administration	
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Although	there	was	an	increase	in	EFI	(improved	endothelial	function)	of	11.3%	at	month	3,	this	did	not	reach	statistical	significance	(95%	CI	-3.175	to	25.79,	p=0.62).	
	
Table	12.	Summary	of	results	obtained	from	radial	artery	applanation	tonometry			 Baseline	 3	months	 Change	 95%	CI	 p	
AIx	 23.30	 24.37	 1.067	 -3.85	to	1.72	 0.433	
EFI	 14.43	 25.74	 11.31	 -3.18	to	25.79	 0.62	
∆	AIx	salbutamol	 -2.90	 -5.07	 2.167	 -0.49	to	4.83	 <0.05	
∆	AIx	GTN	 -18.55	 -20.47	 1.917	 -1.26	to	5.09	 0.126				
o RH-PAT	
17	subjects	had	valid	data	for	assessment	of	endothelial	function	using	RHI.	Due	to	machine	error	4	subjects	did	not	have	both	pre-	and	post-	treatment	readings.	There	was	no	observed	change	in	baseline	RHI	following	3	months	of	testosterone	therapy	(mean	difference	0.06,	95%	CI	-0.19	to	0.31,	p=0.612)	
	
• Subgroup	Analysis	
Subgroup	analysis	by	time	since	menopause	showed	no	significant	difference	between	change	in	AIx,	EFI	or	RHI	between	those	≤	5	years	postmenopausal	(n=16)	and	those	>	5	years	postmenopausal	(n=5)	(table	13)	The	small	numbers	in	each	of	these	subgroups	limit	definitive	conclusions.	
Subgroup	analysis	by	type	of	menopause	(surgical	n=5),	natural	(n=16)	showed	no	significant	difference	between	AIx	(p=0.129),	EFI	(p=0.132)	or	RHI	(p=0.557)	but	analysis	was	also	limited	by	the	small	subgroup	numbers.	
Analysis	was	also	performed	on	women	using	combined	HT	(E+P,	n=16)	and	estrogen	alone	(E,	n=5)(table	14).	Change	in	B-PFSF	score	remained	significant	in	the	E+P	group	but	not	E	alone.	None	of	the	outcome	measures	reached	statistical	significance	in	the	E	
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alone	group	as	the	numbers	were	limited.	A	significant	improvement	in	endothelial	function	as	assessed	by	applanation	tonometry	was	noted	in	the	E+P	group	when	analysed	separately.	This	is	unexpected	and	therefore	needs	to	be	interpreted	with	caution	due	to	the	small	numbers.	
	
Table	13.	Comparison	of	vascular	changes	in	sub	groups	menopause	≤	5	years	
(n=16)	and	>5	years	(n=5).		 	 			 Mean	difference	 	 95%	CI	 	p	
AIx	 -3.02	 	 -9.49	-	3.44	 0.339	
EFI	 20.47	 	 -12.50	-	53.44	 0.209	
RHI	 0.542	 	 -0.55	-	0.65	 0.849		
	
	
Table	14.	Comparison	of	B-PFSF	and	vascular	changes	depending	on	type	of	HT	
	
		 E+P	(n=16)	 E	only	(n=5)	 			 Mean	difference	 95%	CI	 p	 Mean	difference	 95%	CI	 p	 Between	group	p	
		 	 	 	 	 	 	 	B-PFSF	 6.19	 3.34	to	9.04	 <0.0005	 1.4	 -2.87	to	5.67	 0.414	 0.077	
Total	chol	 0.157	 -0.83	to	1.14	 0.736	 -0.04	 -0.77	to	0.69	 0.887	 0.862	
HDL	 -0.06	 0.51	to	0.38	 0.777	 -0.134	 -0.4	to	0.13	 0.232	 0.693	
Lipo	(a)	 -5.071	 -38.28	to	28.14	 0.747	 4.18	 -7.38	to	15.74	 0.372	 <0.05	
HOMA-IR	 0.193	 -0.33	to	0.72	 0.4404	 -0.1	 -0.45	to	0.25	 0.473	 0.398	
	 	 	 	 	 	 	 	AIx	 -0.06	 -3.4	to	3.3	 0.973	 4.63	 -0.2	to	9.5	 0.06	 0.129	
EFI	 17.53	 0.99	to	34.1	 <0.05	 -7.36	 -43.4	to	28.7	 0.6	 0.123	
RHI	 0.02	 -0.3	to	0.3	 0.916	 -0.19	 -0.6	to	0.2	 0.258	 0.557	
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• Correlation/Regression	
o Baseline	
There	were	no	correlations	with	baseline	AIx	or	RHI	and	hormonal,	metabolic	or	vascular	parameters.	
There	was	a	significant	correlation	between	total	cholesterol	and	FAI,	(r	0.49,		cc-.236,	p<0.05)(figure	9).	There	was	also	an	inverse	relationship	observed	between	baseline	SHBG	levels	and	fasting	glucose	(r	0.44,	cc	-.564,	p	<0.05).	
The	2	measures	of	endothelial	function	(EFI	and	RHI)	were	positively	correlated	(r	0.56,	cc	.496,	p<0.05)(figure	10).		
o Post	treatment	
Changes	in	FAI,	total	testosterone	and	SHBG	did	not	correlate	with	changes	in	RHI,	EFI	or	salbutamol	or	GTN	mediated	vasodilatation.	
There	was	no	correlation	with	change	in	FAI/TT	and	anthropometric	measurements,	metabolic	parameters	or	vascular	assessments.	There	was	a	correlation	(r	0.56,	cc	-.610,	p<0.005)	between	change	in	AIx	and	SHBG	(figure	11),	such	that	a	reduction	in	SHBG	was	associated	with	worsening	of	AIx,	but	with	no	other	vascular,	metabolic	or	hormonal	parameters.	There	was	also	an	inverse	association	between	change	in	SHBG	levels	and	change	in	waist	circumference.	(r	0.28,	cc-0.454,	p<0.05).		
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Figure	9.	Correlation	of	baseline	total	cholesterol	with	FAI.	
	
			
Figure	10.	Correlation	of	the	2	baseline	measures	of	endothelial	function	
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Figure	11.	Correlation	of	changes	in	AIx	and	SHBG	
	
		
	
• Additional	effects	and	adverse	events	
Subjectively,	following	12	weeks	of	testosterone	therapy	11	(52%)	participants	reported	improved	energy	levels,	8	(38%)	reported	improved	libido,	(14%)	reported	improved	mood,	2	(9.5%)	improved	concentration	and	1	improved	headaches	(4.8%).	6	(29%)	participants	reported	that	their	overall	effect	from	the	testosterone	patches	was	neutral	during	the	study	period.	6/14	(42.9%)	of	those	with	HSDD	versus	2/7	(28.6%)	without	reported	a	subjective	improvement	in	libido.	This	difference	was	not	statistically	significant	(p=0.66),	however	the	small	subgroup	numbers	limit	the	analysis.	
7	(33%)	participants	experienced	adverse	events	(AE),	all	of	which	were	classified	as	mild	AEs	and	did	not	result	in	discontinuation	of	treatment	(table	15).	4	(19%)	reported	
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skin	irritation	due	to	the	patches,	2	(9.5%)	reported	an	increase	in	facial	hair	(both	gained	1	point	on	Lorenzo	scale	from	baseline),	1	(4.8%)	increased	acne	(classified	as	mild	on	Palatsi	scale),	1	(4.8%)	per	vagina	spotting	(transvaginal	ultrasound	showed	thin	endometrium	of	less	than	4mm)	and	1	(4	.8%)	patient	had	2	episodes	of	blepharitis.	
	
Table	15.	Subjective	effects	of	12	weeks	of	transdermal	testosterone.	n	(%)	
Beneficial	Effects	 	 Adverse	Effects	 	Improved	energy	levels	Improved	libido	Improved	mood	Improved	concentration	Improved	headache	
11	(52%)	8	(38%)	3	(14%)	2	(9.5%)	1	(4.8%)	
Skin	irritation	Hirsutism	Acne	Vaginal	bleeding	Blepharitis	
4	(19%)	2	(9.5%)	1	(4.8%)	1	(4.8%)	1	(4.8%)			 	
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DISCUSSION	
	
CVD	is	the	leading	cause	of	mortality	in	post-menopausal	women	and	the	increase	in	CVD	after	menopause	has	led	to	much	interest	in	the	role	of	sex	steroids	in	its	pathogenesis.	The	potential	cardioprotective	role	of	androgens	is	being	increasingly	recognised,	however	the	implications	for	exogenous	androgen	therapy	have	not	been	well	studied	and	the	effects	of	androgens	remain	poorly	understood,	particularly	in	women.	This	is	the	first	study	to	investigate	the	effects	of	the	transdermal	testosterone	patch,	in	conjunction	with	HT,	on	endothelial	function	and	arterial	stiffness	as	surrogate	markers	of	cardiovascular	risk.		
• Vascular	effects		
In	the	present	study,	transdermal	testosterone	was	associated	with	no	significant	change	in	arterial	stiffness	as	assessed	by	PWA	or	endothelial	function	as	assessed	by	RH-PAT.	However,	PWA	demonstrated	a	significant	improvement	in	endothelium-dependent	(salbutamol-mediated)	vasodilation	after	12	weeks	treatment	and	an	11.3%	improvement	in	overall	endothelial	function,	although	this	was	not	statistically	significant.		
In	the	only	previous	study	investigating	the	effect	of	postmenopausal	testosterone	on	endothelial	function	by	Worboys	et	al,	significant	improvements	in	both	endothelium	dependent	and	independent	vasodilatation	were	observed	after	6	weeks	of	testosterone	implant	therapy	as	assessed	by	FMD(186).	This	study	involved	the	use	of	parenteral	testosterone	resulting	in	supraphysiological	doses,	which	may	act	to	explain	in	part	why	physiological	transdermal	replacement	in	the	present	study	showed	lesser	vascular	effect.	
Testosterone	has	been	recognised	to	act	as	a	vasodilator	in	both	animal	and	human	models	but	the	underlying	mechanisms	are	complex	and	conflicting	data	exist.	In	the	present	study	the	improvement	of	vasodilatation	following	salbutamol	rather	than	GTN	after	testosterone	therapy	points	to	an	endothelium	dependent	mechanism.	
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Animal	data	suggest	that	the	vasodilatory	effects	of	testosterone	are	mainly	through	endothelium	independent	mechanisms,	mediated	for	example	via	changes	in	smooth	muscle	cell	ion	channels	or	genomic	effects	via	the	androgen	receptor	(259–266).	Endothelium	dependent	effects,	mediated	for	example	by	nitric	oxide,	have	also	been	reported	(164,267,268).	It	has	been	suggested	that	the	effect	is	dose	dependent,	with	endothelial	dependent	vasodilatation	occurring	with	physiological	testosterone	levels	and	endothelium-independent	vasodilatation	at	supraphysiological	levels	(124).	
There	are	limited	data	in	humans	exploring	the	mechanism	of	this	effect	and	it	is	unclear	whether	there	may	be	gender	differences.		Studies	in	men	with	coronary	artery	disease	suggested	both	endothelium	dependent	(269)	and	independent	mechanisms	(270).	There	is	evidence	to	support	a	gender	difference	in	the	effects	of	testosterone	as	men	have	greater	AR	expression	in	the	vasculature	than	women	(271),	therefore	results	from	male	studies	cannot	necessarily	be	applied	to	women.		
In	summary,	available	data	point	towards	a	beneficial	vascular	effect	of	testosterone	but	further	large-scale	data	are	required.	Reassuringly,	in	view	of	the	concern	regarding	the	potential	deleterious	CV	effects	of	testosterone	as	cited	by	regulatory	authorities	(3),	physiological	replacement	appears	to	have	no	adverse	impact	on	endothelial	function	or	arterial	stiffness.		
	
• Biochemical	effects	
This	study	found	a	significant	reduction	in	lipoprotein	(a)	levels	at	the	expense	of	a	small	but	significant	reduction	in	HDL	cholesterol.	Lipoprotein	(a)	is	a	strong,	independent	risk	factor	for	cardiovascular	disease	(272)	acting	as	a	pro-atherogenic,	pro-thrombotic	molecule.	In	contrast	to	LDL,	lipoprotein	(a)	levels	are	less	amenable	to	dietary	intervention	or	traditional	treatment	with	statins	(273).	Few	studies	have	examined	the	effect	of	testosterone	on	lipoprotein	(a)	levels.	A	similar	study	investigated	the	effect	of	6	months	of	transdermal	testosterone	gel	(5mg	daily)	in	36	surgically	postmenopausal	women	using	estradiol	(274).	They	reported	a	significant	reduction	in	LDL	cholesterol	with	no	effect	observed	in	triglycerides,	HDL	or	lipoprotein	(a).	The	observed	reduction	in	HDL	cholesterol	in	the	present	study	is	consistent	with	
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prior	studies	investigating	oral	testosterone	(68,180,181),	but	has	not	been	observed	with	transdermal	therapy	(179).		
Administration	of	transdermal	testosterone	had	no	effect	on	fasting	glucose	or	insulin	levels	in	this,	or	other,	TTP	studies	(39,	54,	55).	This	is	the	first	study	to	report	on	the	effect	of	TTP	used	in	conjunction	with	HT	for	low	libido	on	IR	as	assessed	using	the	HOMA-IR	model,	which	is	a	more	accurate	assessment	of	IR	than	fasting	glucose	or	insulin	alone,	and	reassuringly	no	adverse	effects	on	insulin	sensitivity	were	found.	One	previous	study	has	used	the	TTP	in	elderly	women	(mean	age	68.2	years)	with	cardiac	failure,	not	on	HT,	and	found	a	significant	improvement	on	IR	as	assessed	by	HOMA-IR	(213).	
This	study	was	also	able	to	examine	the	effect	of	endogenous	androgen	levels	by	exploration	of	baseline	results,	which	showed	an	inverse	correlation	between	baseline	FAI	and	total	cholesterol.	This	is	in	contrast	to	some	epidemiological	data	(142)	linking	increased	androgenicity	with	adverse	lipid	alterations,	but	in	keeping	with	other	data	(163)	suggesting	that	low	androgen	levels	are	associated	with	CV	risk.		
	
• Systemic	effects	
No	change	was	observed	in	weight,	BMI,	waist	circumference,	or	blood	pressure,	which	corresponds	to	previous	studies	investigating	the	safety	and	efficacy	of	the	TTP.	Alterations	in	body	composition	from	testosterone	may	occur	due	to	changes	in	visceral	fat	or	muscle	mass.	The	effect	on	hip	circumference	was	surprising,	as	prior	studies	have	demonstrated	an	effect	from	testosterone	on	abdominal	(178)	but	not	hip	circumference.	Previous	data	shows	that	the	effect	of	testosterone	on	body	composition	is	very	route	dependent	and	the	majority	of	TTP	studies	have	reported	no	effect	from	physiological	replacement.	
The	improvement	in	B-PFSF	scores	reached	significance	at	6	weeks	and	increased	further	by	12	weeks	of	treatment.	This	improvement	remained	statistically	significant	when	subjects	with	and	without	HSDD	were	analysed	separately.	These	results	suggest	that	even	in	a	group	of	postmenopausal	women	who	do	not	necessarily	fulfil	the	
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diagnostic	criteria	for	HSDD	but	subjectively	complain	of	low	libido,	the	TTP	may	have	a	role.	Prior	studies	have	generally	only	included	women	who	have	HSDD	(39–41,43,55,212)	and	therefore	it	may	be	interesting	to	investigate	the	effect	of	testosterone	further	in	women	whom,	as	in	this	study,	have	a	subjective	complaint	of	distressing	low	sexual	desire.	The	previous	Endocrine	Society	guidelines	(30)	suggested	that	androgen	therapy	should	generally	only	be	recommended	in	women	who	have	undergone	bilateral	oophorectomy,	however	the	recently	updated	guidance	(32)	no	longer	restricts	use	to	surgically	menopausal	women.	This	is	in	keeping	with	the	findings	from	the	current	study	in	which	the	majority	of	women	were	naturally	menopausal	and	still	derived	significant	improvement	in	libido	from	the	TTP.	
Over	50%	of	patients	reported	a	subjective	improvement	in	energy	levels	and	fatigue.	Improvements	in	physical	and	mental	exhaustion	have	also	been	observed	in	women	receiving	testosterone	implants	with	particular	benefit	in	women	with	high	BMI	(33).	Although	in	the	present	study	the	improvement	in	fatigue	was	a	subjective	assessment	and	not	evaluated	using	a	validated	rating	scale,	it	is	another	potential	benefit	from	postmenopausal	testosterone	therapy	which	should	be	investigated	in	future	studies.	Other	reported	benefits	were	improved	concentration	and	headaches,	findings	which	have	also	been	demonstrated	in	other	studies	(33,275).	Androgen	receptors	are	found	in	many	tissues	throughout	the	body	and	therefore	there	are	plausible	mechanisms	as	to	why	the	effects	of	testosterone	therapy	may	be	widespread.	Unfortunately,	the	systemic	effects	of	transdermal	testosterone	other	than	libido	have	not	been	well	studied	in	placebo-controlled	trials	and	therefore	more	data	are	needed	to	confirm	these	findings.	
	
• Hormone	levels	
Although	androgen	levels	have	not	been	shown	to	correlate	well	with	symptoms	of	low	libido,	of	note	all	but	one	subject	had	total	testosterone	levels	in	the	lower	third	of	the	reference	range	at	baseline	(i.e.	<1nmol/L)	and	all	subjects	had	FAI	in	lower	third	of	reference	range.	There	was	no	correlation	between	baseline	FAI	and	B-PFSF	score,	even	
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in	the	HSDD	group,	reiterating	the	recommendations	that	androgen	insufficiency	is	a	clinical	rather	than	biochemical	diagnosis.	
Following	12	weeks	of	treatment,	there	were	significant	increases	in	both	total	testosterone	and	FAI.	Total	testosterone	rose	slightly	above	the	physiological	range	in	only	one	subject	and	FAI	remained	within	physiological	range	in	all	participants.	These	data	help	confirm	that	the	TTP	delivers	physiological	testosterone	levels.	FAI	at	visit	3	did	not	correlate	with	incidence	of	androgenic	side	effects,	as	mean	FAI	was	lower	in	the	group	with	androgenic	side	effects.	The	majority	of	women	involved	had	adequately	replaced	estrogen	at	baseline,	with	only	3	having	low	estradiol	levels	(<100	pmol/L).	As	in	previous	studies	of	the	TTP	(55),	no	changes	in	SHBG	and	estradiol	levels	were	observed	over	the	course	of	this	study.		
• Role	of	SHBG	
In	this	study	a	reduction	in	SHBG	was	associated	with	a	rise	in	AIx	and	waist	circumference.	In	addition,	at	baseline,	there	was	an	inverse	relationship	between	SHBG	and	fasting	glucose.	
The	relationship	between	SHBG	and	fasting	glucose	and	insulin	sensitivity	has	previously	been	recognised	(203,276).	Furthermore,	from	studies	of	endogenous	hormone	levels,	it	has	been	suggested	that	CV	risk	may	be	more	affected	by	SHBG	than	testosterone	(134)	although	it	is	unclear	whether	the	effects	are	truly	independent	of	testosterone	(17).		
Whether	some	of	the	effects	of	exogenous	testosterone	may	be	mediated	through	changes	in	SHBG	remains	unknown.	However,	of	note	in	this	study,	12	weeks	TTP	was	not	associated	with	any	changes	in	SHBG	despite	significant	rises	in	free	and	total	testosterone.	By	avoiding	first	pass	hepatic	metabolism,	transdermal	testosterone	would	be	expected	to	have	minimal	impact	on	SHBG	which	is	largely	regulated	by	hepatic	production.	
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• Study	Limitations	
	
o Study	design	and	population	
This	was	a	pilot	study	and	therefore	has	several	limitations.	Subjects’	baseline	measurements	acted	as	a	control	data	and	therefore	the	lack	of	a	separate	placebo	control	arm	is	a	significant	limitation.	The	original	study	protocol	was	designed	as	a	randomised	placebo-controlled	trial	but	unfortunately	the	manufacturers	ceased	production	of	the	placebo	patch	and	so	the	control	arm	was	withdrawn,	as	no	alternative	placebo	was	available.	As	such	it	is	difficult	to	fully	distinguish	between	potential	androgenic	effects	and	effects	from	continuing	hormone	therapy.	
As	this	was	a	pilot	study	we	had	only	a	limited	sample	size.	However,	even	with	the	small	numbers,	adequate	number	of	recruits	were	obtained	to	detect	a	1	SD	change	in	the	primary	outcome	measures.	The	small	sample	size	limited	the	findings	from	subgroup	analyses	that	may	have	been	relevant,	including	time	since	menopause,	type	of	menopause	(i.e.	natural	or	surgical)	and	type	of	HT,	all	of	which	may	have	an	impact	on	endothelial	response	to	sex	steroids	and	androgen	physiology.	The	study	population	involved	was	not	diverse.	The	women	were	predominantly	Caucasian	(21/22),	of	normal	BMI,	with	minimal	co-morbidities	and	overall	low	CV	risk.	These	findings	cannot	therefore	be	extrapolated	into	other	populations,	although	they	would	still	be	applicable	for	the	majority	of	HT	users.	We	chose	to	recruit	subjects	with	a	subjective	complaint	of	distressing	low	libido,	rather	than	a	formal	diagnosis	of	HSDD.	Recruits	were	all	women	who	would	have	been	offered	testosterone	therapy	within	normal	clinical	practice,	and	as	CV	measures	were	the	primary	outcome	we	felt	that	heterogenenity	in	sexual	function	would	not	adversely	affect	CV	outcomes.	
A	further	limitation	was	the	variable	types	of	concomitant	HT,	although	all	subjects	were	using	estradiol	and	the	majority	were	using	transdermal	or	subcutaneous	preparations.	Due	to	the	small	study	population	it	was	not	possible	to	limit	data	analysis	to	those	on	transdermal/subcutaneous	estradiol	or	particular	progestogens.	Worboys	et	
al.	(186)	have	previously	demonstrated	that	6	weeks	of	subcutaneous	testosterone	(50mg	implant)	in	addition	to	HT	resulted	in	improved	endothelial	function	to	a	control	group	of	non-HT	users.	Their	study	population	also	used	a	variety	of	routes	and	types	of	
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concomitant	HT.	Subgroup	analysis	in	their	study	found	no	difference	in	change	of	FMD	based	on	route	of	estrogen	administration.	
Ideally	the	study	would	have	been	able	to	perform	subgroup	analysis	in	a	larger	number	of	subjects	on	estrogen	alone	to	remove	the	potential	confounding	effects	of	progestogens.	Subgroup	analysis	was	limited	to	5	subjects	on	estrogen	only	therapy	and	therefore	it	is	not	possible	to	draw	meaningful	conclusions.	Additionally,	there	was	also	variation	in	the	use	of	progestogens	amongst	subjects	which	is	of	particular	relevance	as	different	progestogens	can	exhibit	anti-androgenic	(cyproterone	acetate,	dienogest,	drospironone),	androgenic	(LNG,	medroxyprogesterone	acetate,	NET)	or	anti-mineralocorticoid	(drospironone)	effects	which	may	influence	the	effects	of	studies	such	as	this.	Of	the	16	women	using	progestogens,	only	2	were	using	oral	NET.	The	others	were	all	using	either	micronized	progesterone	or	non-oral	LNG	(transdermal	or	IUS),	which	would	be	anticipated	to	have	less	CV	influence	than	oral	NET.	Future	studies	should	aim	to	standardise	concomitant	HT	whilst	examining	the	effects	of	the	TTP.	
Subjects	in	the	present	study	had	a	wide	age	range	of	46-66	years.	It	is	not	clear	if	testosterone,	like	estradiol,	may	have	differing	effects	on	the	vasculature	depending	on	the	duration	post	menopause	and	extent	of	vascular	damage	present.	Subgroup	analysis	of	the	vascular	effects	on	those	less	than	5	years	postmenopausal	and	those	greater	than	5	years	postmenopausal	demonstrated	no	difference	in	change	in	AIx	and	RHI	between	subgroups,	although	the	analysis	was	limited	by	small	numbers.	Studies	have	explored	the	effects	of	subcutaneous	testosterone	implants	in	pre-	and	post-menopausal	women	(33),	but	there	are	no	data	investigating	whether	the	‘timing	hypothesis’,	now	proven	for	estrogen	replacement	(277–280),	also	exists	for	testosterone	replacement.		
o Outcome	measures	
For	the	purposes	of	this	study	we	chose	to	use	surrogate	markers	for	CVD.	The	gold	standard	for	RCTs	is	to	use	CV	events,	however	this	is	only	possible	in	large	scale	studies	with	long	follow-up.	These	are	both	costly	and	time-consuming	and	take	many	years	to	provide	results.	The	use	of	surrogate	markers	is	well	established,	and	in	the	case	of	this	study,	both	RHI	(230)	and	AIx	(234)	have	been	shown	to	correlate	well	with	risk	of	CVD	in	women.	Both	these	methods	provide	a	means	of	detecting	impaired	
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endothelial	function	before	abnormalities	may	be	seen	at	coronary	angiography	and	have	previously	been	used	in	short	term	HT	studies	to	investigate	response	to	treatment	(232)(240).	There	are	several	other	methods	for	assessing	arterial	stiffness	and	endothelial	function,	however	these	methods	were	chosen	as	they	are	simple,	non-invasive	and	reproducible	(229,281).	
RH-PAT	has	several	limitations;	the	finger-probes	are	extremely	sensitive	and	are	thus	pone	to	artefact	from	movement	(although	software	enables	the	removal	of	small	sections	of	artefact).	Endothelial	function	is	affected	by	various	environmental	factors,	which	were	controlled	for	as	much	as	possible	in	the	present	study.	Finger	probes	are	expensive	and	cannot	be	re-used.	Unfortunately,	due	to	machine	error,	4	subjects	had	only	incomplete	RH-PAT	data.		
We	chose	to	use	the	B-PFSF	as	a	tool	for	assessing	libido.	As	the	B-PFSF	only	contains	7	questions	it	does	not	provide	a	detailed	assessment	of	a	woman’s	sexual	functioning,	however	it	has	been	shown	to	discriminate	accurately	between	those	who	have	HSDD	from	those	who	do	not	(253)	and	is	useful	for	assessing	response	to	treatment.	It	has	been	validated	against	more	in	depth	assessments	such	as	the	Profile	of	Female	Sexual	Function	and	has	the	advantages	of	being	a	brief,	self-administered	questionnaire	which	is	easy	to	interpret	(253).	As	sexual	function	was	a	secondary	outcome	measure	we	felt	that	the	B-PFSF	provided	an	appropriate	tool	for	the	purposes	of	this	study.	The	study	did	not	require	in	depth	assessment	of	the	individual	domains	of	female	sexual	function	and,	as	such,	a	brief	global	assessment	to	investigate	response	to	treatment	was	felt	to	be	suitable.	
The	use	of	fasting	glucose	and	insulin	as	markers	of	IR	is	not	well	validated,	particularly	in	healthy	populations	(251)	and	so	we	used	the	homeostasis	model	for	assessing	IR.	HOMA-IR	has	previously	been	used	to	detect	changes	in	IR	in	elderly	women	with	cardiac	failure	using	the	TTP	for	6	months	(213)	and	is	a	more	accurate	method	than	using	fasting	indices	alone.		HOMA-IR	does	have	some	limitations,	particularly	with	the	older,	simplified	mathematical	formula	(248)and	so	IR	was	calculated	using	the	updated	computer	model,	which	has	incorporated	results	from	newer	insulin	assays.	As	insulin	undergoes	pulsatile	secretion,	ideally	the	study	would	have	used	the	mean	value	obtained	from	3	samples	taken	over	5	minutes	(249)	however	this	would	have	been	
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significantly	more	invasive	for	the	study	subjects.	Use	of	3	samples	has	been	reported	to	improve	the	intra-subject	coefficient	of	variance	from	10.3%	for	a	single	sample	to	5.5%	when	3	samples	are	used	(249).		
	
• Study	Strengths	
Only	1	patient	withdrew	from	the	study	prior	to	commencing	treatment,	therefore	biases	associated	with	subject	withdrawal	should	be	negligible.	Even	though	study	numbers	were	small,	recruitment	was	adequate	as	based	on	the	power	calculations	and	missing	data	were	minimal.	Subjects	were	highly	motivated	to	take	part	and	no	study	visits	were	missed.	Use	of	the	TTP	was	associated	with	significant	increases	in	free	and	total	testosterone	level,	implying	good	compliance	and	appropriate	application	amongst	subjects.		
As	only	1	investigator	carried	out	all	study	visits	there	was	no	inter-observer	variability	in	the	arterial	stiffness	and	anthropometric	measurements.	The	validation	study	showed	that	intra-observer	variability	with	PWA	was	comparable	to	published	data.	RH-PAT	is	not	susceptible	to	intra-observer	variability	but	endothelial	function	has	shown	to	be	acutely	susceptible	to	many	environmental	factors,	which	were	well	controlled	for	in	this	study.	All	visits	were	performed	in	controlled	environment,	with	standardised	testing	time,	appropriate	resting	period,	in	a	constant	position	and	a	fasted	state,	with	no	caffeine/alcohol	as	specified	in	the	protocol.	Vascular	measurements	in	this	study	compared	similarly	to	published	data	in	age-matched	populations,	and	there	was	good	correlation	between	the	2	methods	of	endothelial	function	testing,	helping	verify	the	accuracy	of	the	data.	
	
• Androgen	research	
Androgen	research	is	fraught	with	difficulties.	It	remains	unclear	whether	the	effect	of	testosterone	on	the	vasculature	is	mediated	directly	through	the	androgen	receptor,	alternative	non-genomic	pathways	or	through	the	effects	of	local	conversion	to	estrogen	
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via	the	aromatase	inhibitor.	Animal	studies	in	male	mice	suggest	that	both	androgen	receptor	dependent	and	independent	pathways	may	be	responsible	for	the	cardioprotective	role	of	testosterone	(282,283),	however	further	human	data	are	required.		
Studies	involving	testosterone	are	also	highly	susceptible	to	many	confounding	factors,	for	example,	the	increased	aromatase	activity	which	occurs	due	to	age,	obesity,	alcohol,	insulin	resistance,	breast	cancer,	medication,	processed	diet	and	a	sedentary	lifestyle.		
Of	further	difficulty	are	the	inherent	challenges	associated	with	testosterone	measurement,	as	there	has	been	a	lack	of	reliable	assays	and	age-defined	reference	ranges.	Studies	into	androgens	have	used	a	multitude	of	different	assays	of	varying	accuracy	and	the	need	for	sensitive	and	specific	testosterone	assays	has	been	recognised	(32).	
Mass	spectometry	is	usually	considered	the	most	accurate	method	for	assessing	testosterone	levels	but	is	labour	intensive	and	relatively	expensive.	The	direct	immunoassays	(both	radio	and	chemiluminescence)	are	cheaper	and	faster	but	have	the	disadvantage	that	they	may	be	less	accurate,	particularly	at	the	lower	levels	in	women.	The	assay	used	in	this	study	has	been	validated	by	the	Centre	for	Disease	Control	and	Prevention	as	part	of	their	Hormone	Standardization	Program.		
There	is	also	debate	as	to	whether	total,	free	or	bioavailable	testosterone	provides	the	most	clinically	useful	testosterone	fraction	and	the	measurement	of	free	testosterone	is	subject	to	significant	challenges	(284).		The	most	accurate	way	of	measuring	free	testosterone	is	by	either	equilibrium	dialysis	or	ultrafiltration	(32)	and	there	has	been	criticism	of	the	use	of	FAI	(285)	although	in	women	it	has	shown	good	correlation	with	physical	separation	methods	(284).	
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• Future	Studies	
This	study	has	demonstrated	a	useful	protocol	for	the	investigation	of	the	vascular	effects	of	transdermal	testosterone	via	surrogate	markers	of	CVD.	Larger	scale,	placebo	controlled	studies	would	be	very	beneficial	to	examine	further	the	CV	effects	of	testosterone.	Whether	testosterone	acts	through	direct	effects	on	the	vasculature,	indirectly	via	changes	in	body	composition	or	through	its	conversion	to	estradiol	remains	unanswered,	and	data	in	humans	which	help	us	better	understand	its	mode	of	action	would	be	valued.	
Future	studies	should	aim	to	explore	the	effects	of	longer	term	physiological	replacement,	both	with	and	without	concomitant	HT,	and	quantify	more	accurately	the	other	benefits	of	postmenopausal	testosterone	beyond	libido.	Future	research	should	also	address	the	other	safety	concerns	surrounding	postmenopausal	testosterone	including	breast	and	endometrial	effects.	
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CONCLUSION	Unfortunately	few	preparations	are	currently	licensed	for	postmenopausal	testosterone	replacement	in	the	UK.	The	TTP	used	in	the	present	study	was	licensed	for	surgically	postmenopausal	women	with	HSDD	on	concomitant	estrogen	by	the	European	Medicines	Agency	in	2006.	The	patch	has	subsequently	been	withdrawn	from	the	market,	due	to	lack	of	commercial	viability	rather	than	any	safety	concerns.	Transdermal	gels	designed	for	men	are	currently	used	off	label	and	a	testosterone	cream	is	available	in	Australia.	A	survey	of	prescriptions	by	US	physicians	showed	21%	of	prescriptions	for	male	testosterone	products	were	used	by	women	(286),	therefore	there	is	a	great	unmet	need	for	the	development	of	products	designed	for	use	in	women.	In	recognition	that	many	women	are	having	to	use	these	products	designed	for	men	off-license,	current	guidance	has	recommended	that	testosterone	levels	be	checked	at	baseline	and	at	3-6	weeks	and	every	6	months	to	avoid	supra-physiological	levels	(32).	
A	significant	barrier	to	product	development	has	been	the	safety	concerns	raised	by	regulatory	authorities.	It	is	now	clear	now	that	findings	from	older	studies	investigating	supraphysiological	oral	testosterone	cannot	be	applied	to	modern	methods	of	postmenopausal	androgen	replacement,	i.e.	physiological	replacement	via	the	transdermal	route.	This	study	has	shown	the	beneficial	effect	of	the	TTP	on	libido	and	certain	markers	of	CV	health.	This,	along	with	previous	studies,	has	not	suggested	any	deleterious	CV	effects	from	physiological	testosterone	replacement.	Furthermore	there	are	much	published	data	in	support	of	the	many	benefits	of	androgen	replacement.	This	greater	understanding	of	the	benefits	and	long-term	effects	of	testosterone	will	hopefully	stimulate	the	development	of	products	designed	specifically	for	use	in	women.		
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Appendix	1.	
Palatsi	Scale:	Degree	of	Facial	Acne	Vulgaris	
	
Severity	of	Acne	
Grade	0:	 The	facial	area	is	perfectly	clear	or	contains	only	a	few	small	lesions.	
Grade	1:	 Mild	acne.	A	few	pustules	and	about	10	papules	are	present.	
Grade	2:	 Moderate	acne.	About	half	the	face	is	affected	and	numerous	lesions	are	
present.	
Grade	3:	 Severe	acne.	Numerous	lesions	and	general	inflammation	of	the	facial	skin	is	
present.	
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Appendix	2.	
Lorenzo	Scale	for	assessment	of	facial	hirsutism	
	
	
	
	
Upper	Lip	0 No	Hair	1 A	few	scattered	hairs	2 A	small	moustache	emerging	from	the	outer	margins	3 A	moustache	extending	halfway	from	the	outer	margins	4 Heavier	growth	with	fusion	in	midline	
	
Chin	 0 No	hair	1 A	few	scattered	hairs	2 Scattered	hairs	with	small	concentrations	3 Complete	cover	light	4 Complete	cover	heavy	
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Appendix	3.	Permissions	
	
